Podcasts about New York Medical College

In today's episode, we dive into the science of hair restoration with Dr. Alan Bauman. As the founder of Bauman Medical and a prominent hair restoration physician, Dr. Bauman has committed more than 20 years of his career to treating hair loss. He is known for his multi-therapy approach to hair restoration – combining many diverse techniques to help patients enhance, maintain, and restore their hair…  Join the conversation to find out: What drew Dr. Bauman to this unique field of medicine.  How hair restoration has evolved and improved over the years.  Factors that contribute to hair thinning. The difference between hair plugs and modern hair transplants. Preventative treatments for hair loss.  Why hair is such an important part of people's self-image.  Dr. Bauman earned his medical doctorate from New York Medical College in Valhalla, NY. He completed his internship and residency in surgery at Beth Israel Medical Center and Mount Sinai Medical Center in Manhattan before moving into the field of hair transplant surgery and the treatment of hair loss, with a primary focus on androgenetic alopecia — otherwise known as hereditary male or female pattern hair loss. To learn more about Dr. Bauman and his work, visit the Bauman Medical website! Episode also available on Apple Podcast: http://apple.co/30PvU9C

In this episode, Westchester Talk Radio host Bob Marrone speaks with Dr. Vikas Grover, Chair of Rehabilitation Sciences at New York Medical College and one of the distinguished honorees at Westchester Magazine's Healthcare Heroes Luncheon on May 15th, 2025, held at Mulino's at Lake Isle Country Club in Eastchester, NY. The event celebrated individuals who have made a profound impact on healthcare in the community, with stories of dedication and compassion showcased in the May issue of Westchester Magazine. Dr. Grover shares his perspective on rehabilitation sciences and the importance of education and innovation in patient care. Tune in for an inspiring conversation from a day dedicated to recognizing healthcare excellence. 

In this inspiring episode of Parallax, Dr Ankur Kalra engages with Dr Srihari S. Naidu, current President of the Society for Cardiovascular Angiography and Interventions (SCAI) and tenured professor at New York Medical College. Their conversation explores Dr Naidu's compelling journey from his formative years and family influences to his strategic vision for elevating interventional cardiology's national profile. Dr Naidu shares his innovative "LINK" philosophy—Leadership, Innovation, Networking, and Knowledge—which has guided his approach to medicine and leadership. The discussion delves into SCAI's remarkable growth in education, publications, and advocacy under his stewardship, while addressing the critical need to increase public understanding of interventional cardiologists' life-saving contributions to healthcare. The conversation offers valuable insights on career progression in medicine, exploring the delicate balance between knowledge and wisdom across different career stages. Dr Naidu provides thoughtful perspectives on the "sweet spot" of mid-career practice, the importance of cross-generational learning, and SCAI's commitment to fostering diversity by removing barriers for women and underrepresented groups in the field. Essential listening for cardiologists at all career stages, healthcare leaders, and those interested in the evolving landscape of interventional cardiology and its impact on patient care and public health. Buy the SCAI Cap here. (https://shop.scai.org/) Questions and comments can be sent to "podcast@radcliffe-group.com" and may be answered by Ankur in the next episode. Host: @AnkurKalraMD and produced by: @RadcliffeCardio Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.

Mara De Luca's (b. 1973, Washington D.C.) paintings evoke a sense of atmospheric abstractions that bring to mind dusk, sunsets, and planetary orbs. Throughout her work there is a sense of reflected ambient light. De Luca's work today extends the celebration of illusionism, romanticism, and the sublime with a deeply informed response to modernist painting. De Luca received an MFA from CalArts, Los Angeles, CA and a BA from Columbia University, NY. Her work has been displayed at the Museum of Contemporary Art, San Diego and is in prominent collections, including the Buck Collection at UC Irvine, JP Morgan Chase, New York; Fidelity, Boston; Alexander Plaza Berlin, Germany; New York Medical College, New York; and the University of Oslo, Norway. She has been reviewed in Artforum, Cultured Magazine, The Los Angeles Times, Artweek LA, and others. De Luca is a recipient of the 2019 California Community Foundation Fellowship for Visual Artists. She has taught Painting at UC San Diego, UC Irvine, UC Davis and UC Riverside. Based in Los Angeles for over two decades, De Luca now lives and works in New York. Mara De Luca, Western Gate 1, 2024 mixed media on canvas with copper plated element 54 × 96 inches (137 × 244 cm) Mara De Luca, Western Gate 2, 2024 acrylic on primed and unprimed canvas with brass plated element 59 x 132 inches (150 x 335.5 cm) Mara De Luca, Cut Western Clouds, 2024, mixed media on cut canvas with copper plated elements, 48 x 42 x 3 inches (122 x 106.5 x 7.5 cm).

Surgical conferences are a forum of the profession–where we all gather to socialize, share clinical experiences, promote academic work, and learn from each other. But what goes into putting these conferences together? In this next installment of the BTK/ASGBI collaborative series, Jon Williams and ASGBI co-hosts Kellie Bateman and Jared Wohlgemut welcome Mr. Dimitrios Damaskos from Edinburgh and Dr. Anne Lidor from the University of Wisconsin to take a look behind the scenes of conference planning. We'll cover logistics, program selection, how surgical societies strive to support their members and trainees, and much more! Mr Dimitrios Damaskos, initially from Greece, he came to the UK for his fellowship and is a UGI and Emergency General Surgical Consultant with an interest in abdominal wall surgery based in The Royal Infirmary Edinburgh. He is the current Director of Scientific Programme for ASGBI and responsible for organising our main International Congress which this year happens to be in Edinburgh. He has also held numerous other events for surgical societies including the British Hernia Society. Dr. Lidor serves as the program chair for the Society for American Gastrointestinal and Endoscopic Surgeons (i.e. SAGES), which is a wide-reaching US-based international surgical society that encompasses many facets of general surgery. The SAGES Annual Meeting was just last month, and is a great opportunity for surgeons to convene and share clinical experiences, academic work, and professionally connect. Dr. Lidor completed medical school at the New York Medical College, and then moved on to George Washington University for general surgery residency training. Following residency, she moved to Baltimore to Johns Hopkins where she completed her MIS/Bariatric Surgery fellowship and subsequently stayed on as a faculty surgeon. After years at Hopkins during which she held many education leadership roles both at the medical school and as fellowship director, she moved to the University of Wisconsin to become Chief of Minimally Invasive and Bariatric Surgery, a role she continues to hold today.  If you enjoyed this episode, stay tuned for more upcoming BTK/ASGBI collaborative content. If you have any questions or comments, please feel free to reach out to us at hello@behindtheknife.org.  Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

Dr. Denis Bouboulis is a leading specialist in Neuro-Immunology, known for his pioneering work in diagnosing and treating PANS/PANDAS, which is a Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus (PANDAS), autoimmune encephalitis, and tick-borne illnesses like Lyme disease. As the Founder and Director of Superior Associates Infusion Center and head of Advanced Allergy, Immunology & Asthma in Connecticut, he has successfully treated thousands of patients whose conditions were often overlooked or misdiagnosed. With over 13 years of experience as a board-certified physician and a medical degree from New York Medical College, Dr. Bouboulis is committed to raising awareness and delivering cutting-edge care for both common and complex immune-related conditions.   In today's episode of Conversations on Healing, host Shay Beider welcomes Dr. Denis Bouboulis to discuss vector-borne illness, Long COVID, PANS/PANDAS, and the body's immune response. The two discuss how vector-based infections like Lyme disease and parasitic bacteria can remain dormant until a triggering event—such as COVID-19—causes a breakdown in the immune system, leading to symptomatic and chronic illness. Dr. Bouboulis also talks about autoimmune encephalitis, particularly how the basal ganglia is affected and why a holistic, interdisciplinary approach is essential for proper diagnosis and treatment. He shares how he treats some of these autoimmune diseases, and offers hope to patients.   Listen to the complete episode by clicking the player above. Transcripts for this episode are available at: https://www.integrativetouch.org/conversations-on-healing    Show Notes: Check out Dr. Bouboulis here Learn more about the Advanced Allergy, Immunology & Asthma here   This podcast was created by Integrative Touch (InTouch), which is changing healthcare through human connectivity. A leader in the field of integrative medicine, InTouch exists to alleviate pain and isolation for anyone affected by illness, disability or trauma. This includes kids and adults with cancers, genetic conditions, autism, cerebral palsy, traumatic stress, and other serious health issues. The founder, Shay Beider, pioneered a new therapy called Integrative Touch™Therapy that supports healing from trauma and serious illness. The organization provides proven integrative medicine therapies, education and support that fill critical healthcare gaps. Their success is driven by deep compassion, community and integrity.  Each year, InTouch reaches thousands of people at the Integrative Touch Healing Center, both in person and through Telehealth. Thanks to the incredible support of volunteers and contributors, InTouch created a unique scholarship model called Heal it Forward that brings services to people in need at little or no cost to them. To learn more or donate to Heal it Forward, please visit IntegrativeTouch.org  

You're losing hair… but is stress to blame?”Join us with globally recognized hair transplant surgeon Dr. Alan J. Bauman, MD, ABHRS, IAHRS, FISHRS, as he explains how stress impacts your scalp health—and what you can do to stop or even reverse the damage.Since founding Bauman Medical in Boca Raton, Florida, in 1997, Dr. Bauman has personally treated over 34,000 patients and performed more than 12,000 hair transplant surgeries. His compassionate, patient-first approach and artistic eye for restoration have made him one of the most sought-after hair loss specialists worldwide.He earned his M.D. from New York Medical College and completed his surgical residency at Mt. Sinai Medical Center and Beth Israel Medical Center in New York City. Dr. Bauman is board certified by the American Board of Hair Restoration Surgery (ABHRS), a Fellow of the International Society of Hair Restoration Surgery (FISHRS), and a member of the International Alliance of Hair Restoration Surgeons (IAHRS). ​Throughout his career, Dr. Bauman has received numerous accolades, including being voted "America's #1 Top Hair Restoration Physician" for eight consecutive years and being awarded "Hair Restoration Surgeon of the Decade" by Aesthetic Everything. Forbes recognized him as a "Top 5 Transformative CEO" and one of "Ten CEOs Transforming Healthcare in America." ​He holds advisory positions with organizations such as the World Trichology Society and has been involved in the research and development of advanced hair loss treatments. His expertise has been featured across various media platforms, including his YouTube channel, where he educates viewers on hair restoration topics.

About our guest:Ilyse Genser is a pediatric neurologist and the associate program director of the pediatric neurology combined residency program at Children's National Hospital. She is originally from Westchester, New York, where she attended medical school at New York Medical College. She then completed her general pediatrics training at Brown University in Providence, Rhode Island, and came to Washington, D.C., to complete her child neurology training at Children's National Hospital. Learning Objective:Develop an expert-guided approach to choosing appropriate neuroimaging techniques for critically ill children.References: Shulman, J. G., & Abdalkader, M. (2023). Imaging of Central Nervous System Ischemia. http://journals.lww.com/continuumHakimi, R. (2023). Imaging of Central Nervous System Hemorrhage. http://journals.lww.com/continuumJordan, J. T., & Gerstner, E. R. (2023). Imaging of Brain Tumors. http://journals.lww.com/continuumBarnette, A. R., Horbar, J. D., Soll, R. F., Pfister, R. H., Nelson, K. B., Kenny, M. J., Raju, T. N. K., Bingham, P. M., & Inder, T. E. (2014). Neuroimaging in the Evaluation of Neonatal Encephalopathy. PEDIATRICS, 133(6), e1508–e1517. https://doi.org/10.1542/peds.2013-4247Questions, comments or feedback? Please send us a message at this link (leave email address if you would like us to relpy) Thanks! -Alice & ZacSupport the showHow to support PedsCrit:Please complete our Listener Feedback SurveyPlease rate and review on Spotify and Apple Podcasts!Donations are appreciated @PedsCrit on Venmo , you can also support us by becoming a patron on Patreon. 100% of funds go to supporting the show. Thank you for listening to this episode of PedsCrit. Please remember that all content during this episode is intended for educational and entertainment purposes only. It should not be used as medical advice. The views expressed during this episode by hosts and our guests are their own and do not reflect the official position of their institutions. If you have any comments, suggestions, or feedback-you can email us at pedscritpodcast@gmail.com. Check out http://www.pedscrit.com for detailed show notes. And visit @critpeds on twitter and @pedscrit on instagram for real time show updates.

About our guest:Ilyse Genser is a pediatric neurologist and the associate program director of the pediatric neurology combined residency program at Children's National Hospital. She is originally from Westchester, New York, where she attended medical school at New York Medical College. She then completed her general pediatrics training at Brown University in Providence, Rhode Island, and came to Washington, D.C., to complete her child neurology training at Children's National Hospital. Learning Objective:Develop an expert-guided approach to choosing appropriate neuroimaging techniques for critically ill children.References: Shulman, J. G., & Abdalkader, M. (2023). Imaging of Central Nervous System Ischemia. http://journals.lww.com/continuumHakimi, R. (2023). Imaging of Central Nervous System Hemorrhage. http://journals.lww.com/continuumJordan, J. T., & Gerstner, E. R. (2023). Imaging of Brain Tumors. http://journals.lww.com/continuumBarnette, A. R., Horbar, J. D., Soll, R. F., Pfister, R. H., Nelson, K. B., Kenny, M. J., Raju, T. N. K., Bingham, P. M., & Inder, T. E. (2014). Neuroimaging in the Evaluation of Neonatal Encephalopathy. PEDIATRICS, 133(6), e1508–e1517. https://doi.org/10.1542/peds.2013-4247Questions, comments or feedback? Please send us a message at this link (leave email address if you would like us to relpy) Thanks! -Alice & ZacSupport the showHow to support PedsCrit:Please complete our Listener Feedback SurveyPlease rate and review on Spotify and Apple Podcasts!Donations are appreciated @PedsCrit on Venmo , you can also support us by becoming a patron on Patreon. 100% of funds go to supporting the show. Thank you for listening to this episode of PedsCrit. Please remember that all content during this episode is intended for educational and entertainment purposes only. It should not be used as medical advice. The views expressed during this episode by hosts and our guests are their own and do not reflect the official position of their institutions. If you have any comments, suggestions, or feedback-you can email us at pedscritpodcast@gmail.com. Check out http://www.pedscrit.com for detailed show notes. And visit @critpeds on twitter and @pedscrit on instagram for real time show updates.

Achieving Success with Olivia Atkin Episode 120 "Achieving Understanding: The Science, Stigma, And Future Of Epilepsy Care with Dr. Tracey Milligan"Olivia talks personal and professional achievements with Dr. Tracey Milligan. Dr. Tracey A. Milligan, Chair of Neurology at New York Medical College and Director of Neurology at Westchester Medical Center Health Network. With over 20 years of experience, Dr. Milligan is a leading expert in epilepsy and a champion for medical education. Her impressive journey includes degrees in Communication Disorders and Speech-Language Pathology, a medical degree from Albert Einstein College of Medicine, and residency and fellowship training at Harvard. Dr. Milligan has been recognized for her leadership in diversity, her innovative Spanish Neurology Clinic, and her dedication to teaching, earning numerous awards for her contributions to healthcare and education. Today, we'll dive into her journey and insights on advancing neurology and fostering impactful change.Join Olivia every Tuesday as she brings on top notch guests to talk about how they are Achieving Success! Career Development Book and More at Achieving-success.comStay Connected With Us:Linkedin: https://www.linkedin.com/company/achieving-success-llcInstagram: @_achievingsuccessTwitter: @_achievesuccessFacebook: @Achieving SuccessBecome a supporter of this podcast: https://www.spreaker.com/podcast/achieving-success-with-olivia-atkin--5743662/support.

Dr. Jason T. Jacobson, MD, FHRS, Westchester Medical Center, New York Medical College is joined by Melissa Robinson, MD, FHRS, Providence Heart Institute of Montana, and Dr. Sei Iwai, MD, FHRS, Westchester Medical Center, New York Medical College to discuss: BACKGROUND Factors determining hemodynamic stability during human ventricular tachycardia (VT) are incompletely understood. OBJECTIVES This study aimed to characterize sinus rate (SR) responses during monomorphic VT in association with hemodynamic stability and prospectively assess the effects of vagolytic therapy on VT tolerance. METHODS This is a retrospective analysis of patients undergoing scar-related VT ablation. Vasovagal responses were evaluated by analyzing sinus cycle length before VT induction and during VT. SR responses were classified into 3 groups: increasing ($5 beats/min, sympathetic), decreasing ($5 beats/min, vagal), and unchanged, with the latter 2 categorized as inappropriate SR. In a prospective cohort (n . 30) that exhibited a failure to increase SR, atropine was administered to improve hemodynamic tolerance to VT. RESULTS In 150 patients, 261 VT episodes were analyzed (29% untolerated, 71% tolerated) with a median VT duration of 1.6 minutes. A total of 52% of VT episodes were associated with a sympathetic response, 31% had unchanged SR, and 17% of VTs exhibited a vagal response. A significantly higher prevalence of inappropriate SR responses was observed during untolerated VT (sustained VT requiring cardioversion within 150 seconds) compared with tolerated VT (84% vs 34%; P < 0.001). Untolerated VT was significantly different between groups: 9% (sympathetic), 82% (vagal), and 32% (unchanged) (P < 0.001). Atropine administration improved hemodynamic tolerance to VT by 70%. CONCLUSIONS Nearly one-half of VT episodes are associated with failure to augment SR, indicative of an underrecognized pathophysiological vasovagal response to VT. Inappropriate SR responses were more predictive of hemodynamic instability than VT rate and ejection fraction. Vagolytic therapy may be a novel method to augment blood pressure during VT.   https://www.hrsonline.org/education/TheLead https://www.jacc.org/doi/10.1016/j.jacc.2023.06.033 Host Disclosure(s): J. Jacobson: Honoraria/Speaking/Consulting: Zoll Medical, Abbott Medical, Vektor Medical, Stocks, Privately Held: Atlas 5D, Research: CardioFocus, Inc.   Contributor Disclosure(s): M. Robinson: Honoraria/Speaking/Consulting: Biosense Webster, Inc., Boston Scientific, Abbott, Membership on Advisory Committees: Medtronic Inc. S. Iwai: Honoraria/Speaking/Consulting: Alta Thera Pharmaceuticals, Biotronik

In this episode, Lawrence shares his transformative journey from a life-threatening diagnosis of lymphosarcoma to a profound spiritual awakening guided by a master he had recently met. He recounts his extraordinary healing experience at a major university hospital in New York City and the subsequent life changes that led him to study Eastern traditions and become a monk. Lawrence delves into concepts of Kundalini, yoga, and the infinite consciousness, explaining how these practices inform our spiritual evolution across lifetimes. The conversation explores how experiences of divine presence can transform our ordinary existence, urging us to embrace our true nature and serve the world with compassion and wisdom. Lawrence encourages listeners to embark on their spiritual journey and provides resources for further exploration. About Lawrence: Lawrence Edwards is a neurotherapist, psychotherapist, and an expert in Kundalini Awakening, our innate power of Consciousness that creates the highest order of transformation and revelation. This power is the foundation of all yogic, mantra and meditation practices. Lawrence is regarded by many as a modern mystic known for his love of the Divine. He is unusual in this field because he has a deep grounding in both Eastern and Western traditions, and applies them both to his work with Kundalini.  His personal, direct, life-long experience of the extraordinary power and grace of Kundalini are reflected in his writings, teaching and poetry.  His experiences began early in life and he says Kundalini's grace continues to be the essence of his life. Lawrence is the president of The Kundalini Research Network, as well as the founder of a Kundalini support website, KundaliniSupport.org. He is the founder and director of the Anam Cara Foundation and a contributing author to the Sounds True anthology Kundalini Rising: Exploring the Energy of Awakening. Lawrence has practiced and taught meditation for over 46 years and has been on the faculty of New York Medical College since 1998. He is the author of the critically acclaimed book on Kundalini, The Soul's Journey: Guidance From The Divine Within and Kali's Bazaar. He leads retreats on the Mysteries of the Divine Feminine and Awakening Kundalini. Key Points Discussed:  (00:00) - Unlock The IMMENSE POWER Within You: WHY More People Are Waking Up to This Truth (00:55) - Republishing the Episode (01:38) - Introduction to Lawrence (02:08) - Lawrence's Journey to Transformation (03:16) - Transcendent Experiences and Healing (09:52) - The Lady of Light (12:00) - Early Spiritual Experiences (15:05) - Understanding Kundalini and Consciousness (27:04) - The Reality of Kundalini (27:29) - The Power of Transformation (27:42) - Classical Forms of Yoga (28:19) - Spontaneous Yoga Practices (28:59) - Navigating Kundalini Awakening (30:57) - The Role of Fear and Anger (31:42) - The Importance of a Teacher (33:22) - Spontaneous Awakenings (34:23) - The Longing to Know (34:56) - Discrimination in Spiritual Practice (38:33) - The Ego Mind and Kundalini (41:38) - Transformative Experiences (45:19) - The Dark Age and Dharma (48:48) - Mantra and Sacred Sound (52:57) - Living in the Divine's Embrace How to Contact Lawrence Edwards: Twitter – twitter.com/MeditationDoc Website – www.thesoulsjourney.com   About me:My Instagram: www.instagram.com/guyhlawrence/?hl=en Guy's websites:www.guylawrence.com.au www.liveinflow.co''

Today, we explore the recent compendium of responsa called Shu"T PUAH, produced by PUAH, an organization that helps families with the range of challenges in the fertility journey, including halacha, medicine, finances, counseling and more. We had the privilege to hear from Rabbi Elan Segelman, PUAH's rabbinic director in America. We explore different perspectives on artificial insemination and surrogacy - and walk away with an appreciation for the important work PUAH is doing within the realm of responsa and the real lived experience.  Rabbi Elan Segelman is the rabbinic director for PUAH in America. After studying in Israel for two years at Yeshivat Kerem B'Yavneh, Rabbi Segelman attained a B.A. in Psychology from Touro College's Lander College for Men, as well as an M.A. from Touro College's Graduate School of Jewish Studies. Shortly after completing his Semicha, he was appointed as a Shoel U'Maishiv and Rebbe in the Lander College Judaic Studies Program. In 2016, Rabbi Segelman became the Rabbinic Educator at New York Medical College & Touro College of Dental Medicine in Valhalla, NY. Rabbi Segelman currently resides in Los Angeles, California, where he serves as the Rabbi of the Young Israel of Hancock Park. He can be reached at: esegelman@puahfertility.org To learn more about PUAH, click here. To purchase their books, click here.

Begin your hair restoration today: https://www.baumanmedical.com/Dr. Alan J. Bauman, MD, ABHRS, IAHRS, FISHRS is a full-time hair transplant surgeon who founded his medical practice in Boca Raton, Florida in 1997 and has treated over 34,000 patients and performed over 12,000 hair transplant surgeries to date. His compassionate, patient-centered philosophy and individualized artistic approach to protecting, enhancing and restoring the appearance and health of the hair and scalp is what sets him apart from non-specialists and other practitioners. Dr. Bauman moved to Boca Raton with his wife Karen after receiving his M.D. degree from New York Medical College, doing his surgical residency training at Mt. Sinai Medical Center and Beth Israel Medical Center in Manhattan, and completing his hair transplant Fellowship training in New York.Dr. Bauman is one of only approximately 200 physicians worldwide to achieve certification from the esteemed American and International Board of Hair Restoration Surgery (ABHRS), be an accepted member of the International Alliance of Hair Restoration Surgeons (IAHRS) and also recommended by the American Hair Loss Association. Dr. Bauman achieved the coveted Fellow status within the International Society of Hair Restoration Surgery (FISHRS) and is a frequently invited faculty member at numerous international scientific meetings, live surgery workshops, and major beauty industry events.Dr. Bauman is the first-ever hair transplant surgeon to be formally accepted as an Intercoiffure America/Canada Industry Partner; Intercoiffure is the most powerful and influential organization in the hairdressing industry. He is also an Advisory Board Member for the World Trichology Society and an active Trustee-Level Member of the Greater Boca Raton Chamber of Commerce; he credits part of his early and ongoing success thanks to his involvement in local and national professional networks. He is also the author of numerous articles and textbook chapters on the science of hair care and hair transplantation, including eyelash transplant surgery, and has been extensively featured in the world's leading mass media as a medical expert and successful early-adopter and pioneer of some of the most advanced technologies in the effective treatment of hair loss. Dr. Bauman's international reputation and his exceptional team at Bauman Medical attracts patients from all corners of the globe for hair loss diagnosis and the latest and most effective hair restoration treatments and procedures.Recently, Dr. Bauman was named both a “Top 5 Transformational CEO” and one of “The 10 CEOs Transforming Healthcare in America” in Forbes, voted North America's “#1 Top Hair Restoration Surgeon” by Aesthetic Everything for 8 consecutive years and awarded "Hair Restoration Surgeon of the Decade." His accessible and interactive presence on social media has garnered millions of video views on YouTube and thousands of subscribers, connections and followers on the most popular platforms. A recent Live Hair Transplant Surgery broadcast directly from the procedure room in his Boca Raton office gained over 100,000 simultaneous views from more than 20 countries. Dr. Bauman also has been a member of the highly respected Pantene Hair Research Institute, a global network of leading hair experts focused on the advancement of hair science, technologies, and products. He is currently serving as an inaugural Luminary Board Member for Church & Dwight (NYSE: CHD). As an industry thought-leader and innovator, his advice is often sought by numerous companies and institutions in the field of hair loss, aesthetics, anti-aging, and beyond.In a long tradition of community service and philanthropy, Dr. Bauman has been a participating member and financial supporter of the International Society of Hair Restoration Surgery's Pro Bono Foundation, a founding member of the Bauman Philanthropic Foundation 501c3 non-profit organization, and he dedicates his spare time as the Medical Director and a Founding Board Member of Grey Team, a Boca Raton-based 501c3 non-profit organization focused on assisting active US military and US military veterans in their journey toward improved mental and physical health and preventing PTSD-related suicide.In addition to serving as the CEO of Bauman Medical and teaching and consulting internationally, Dr. Bauman personally treats patients at his nearly 12,000 sq. ft. Bauman Medical Hair Transplant and Hair Loss Treatment Center in beautiful oceanside Boca Raton, Florida.Connect with Me:Got more questions or thoughts about today's episode? Send them my way on Instagram @travischappell! I'd love to hear from you.Visit https://porkbun.com/BuildYourNetwork24 and get your .PRO domain for just $1 for the first year at Porkbun!Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Ready to diversify outside the stock market? EquityMultiple brings you streamlined real estate investing. Access vetted, cash-flowing opportunities from anywhere. Start today, with just $5K, at equitymultiple.com________What does the future hold for U.S. healthcare? In this podcast episode, Dr. Bradley Block interviews Adam Block, an associate professor of health policy at New York Medical College, to discuss the potential future of U.S. healthcare under the Trump administration.Key topics include the possible introduction of Medicaid block grants and work requirements—policies aimed at reducing state healthcare spending but potentially increasing administrative challenges. Adam Block predicts the continuation of popular programs like Medicare Advantage and telemedicine while raising concerns about controversial leadership appointments, such as Robert F. Kennedy Jr. at the U.S. Department of Health and Human Services.The conversation covers important topics like lowering drug prices, improving healthcare in rural areas, and the ongoing debate over whether private companies or the government run healthcare better. Dr Adam Block also looks back at how the COVID-19 pandemic was handled, pointing out what could have been done better and why being prepared is so important.He stresses the need for quick action on new healthcare laws at the start of a new administration, as there's only a short time to make big changes before political priorities shift.Bio.Adam Block is an associate professor of health policy at New York Medical College and a seasoned expert in health economics. He is the founder and CEO of Charm Economics, a boutique consulting firm specializing in economic modeling for digital health and medical technology companies, as well as assisting with legal damage estimation.His career includes serving as the director of strategic planning at Montefiore Medical Center in the Bronx and as the director of medical economics at Fidelis Care, New York's largest Medicaid plan. Notably, Adam spent five years contributing to the development of the Affordable Care Act and later worked as a regulator at the Centers for Medicare & Medicaid Services (CMS).Website:https://www.charmeconomics.com/Socials:LinkedIn: https://www.linkedin.com/in/adameblock/ _________Dr. Bradley Blocks' BioFind more about Dr. Block here: https://www.physiciansguidetodoctoring.com/mediaDid you know… You can also be a guest on our show? Please email me at brad@physiciansguidetodoctoring.com to connect or visit www.physiciansguidetodoctoring.com to learn more about the show!Socials:@physiciansguidetodoctoring on FB @physicianguidetodoctoring on YouTube@physiciansguide on Instagram and Twitter Visit www.physiciansguidetodoctoring.com to connect, dive deeper, and keep the conversation going. Let's grow! Disclaimer:This podcast is for informational purposes only and is not a substitute for professional medical, financial, or legal advice. Always consult a qualified professional for personalized guidance.

Step into the fascinating world of plastic surgery with Dr. Ilana Margulies, a PGY5 integrated plastic surgery resident at MedStar Georgetown University Hospital. In this episode, Dr. Margulies shares her journey through medicine, blending technical mastery with a deep understanding of psychology to transform lives through plastic surgery. Dr. Margulies sheds light on the complexity of the field, from aesthetic and reconstructive procedures to the intricate art of microsurgery. She explains how plastic surgery isn't just about physical transformation but also involves addressing the emotional and psychological needs of patients. The conversation delves into her groundbreaking research, her leadership roles within the Plastic and Reconstructive Surgery Journal's Resident Advisory Board, and her vision for a career in general and complex microsurgical reconstruction. This episode is a must-listen for anyone curious about the blend of science, art, and humanity that defines plastic surgery. Tune in for an enlightening discussion that goes beyond the surface and into the heart of what makes this field so unique. Ilana Margulies, MD, MS is a PGY5 integrated plastic surgery resident at MedStar Georgetown University Hospital in Washington, DC. She completed her undergraduate studies in Biology with honors at New York University and then completed a Masters in Biomedical Sciences at the Icahn School of Medicine at Mount Sinai. She then earned her MD at New York Medical College with Global and Population Health Area of Distinction, and was inducted into the Alpha Omega Alpha Honors Medical Society. During medical school she pursued a research fellowship in plastic surgery at the Icahn School of Medicine at Mount Sinai. She has authored over 30 peer reviewed publications and presented at numerous conferences. She is also very involved in the resident advisory board of the Plastic and Reconstructive Surgery Journal and the Jewish Plastic Surgeons Forum. She hopes to pursue a career in general and complex microsurgical reconstruction. When out of the hospital, she enjoys spending time with her husband, two daughters, and golden retriever. _________________________________________________ Sponsor the JOWMA Podcast! Email digitalcontent@jowma.org Become a JOWMA Member! www.jowma.org Follow us on Instagram! www.instagram.com/JOWMA_org Follow us on Twitter! www.twitter.com/JOWMA_med Follow us on Facebook! https://www.facebook.com/JOWMAorg Stay up-to-date with JOWMA news! Sign up for the JOWMA newsletter! https://jowma.us6.list-manage.com/subscribe?u=9b4e9beb287874f9dc7f80289&id=ea3ef44644&mc_cid=dfb442d2a7&mc_eid=e9eee6e41e

Join us for the 5th Annual JOWMA Conference: Transforming Healthcare Through Innovation & Research on January 5, 2025, from 8am to 5pm in NYC! Spend the day immersed in expert-led scientific sessions, hands-on surgical simulations, specialty roundtables, and a networking lunch tailored for healthcare professionals and students. PLUS, we're offering a full premed program with panels, roundtables, and networking dedicated to aspiring medical students.

Support the show and get 50% off MCT oil with free shipping – just leave us a review on iTunes and let us know!https://podcasts.apple.com/us/podcast/live-beyond-the-norms/id1714886566 Is your hair thinning? What if you could turn back the clock on hair loss - without resorting to hats, wigs, or comb-overs? The vast majority of patients seeking treatment for hair loss have a hereditary component - but that doesn't mean you're powerless against baldness. Dr. Alan Bauman has spent over 25 years helping people keep the hair they have, restore the hair they've lost, and feel confident in their own skin (and scalp!). From cutting-edge laser therapy to PRP treatments, Dr. Bauman is on a mission to make baldness obsolete.In today's episode, you'll learn how your diet, sleep, and stress levels impact your follicles, why your hair is an early warning system for your health, and what you can do today to ensure a full head of hair tomorrow."The earlier you seek treatment, the better off you're going to be. It's an investment that keeps on growing." ~Dr. Alan BaumanAbout Dr. Alan Bauman:Dr. Alan Bauman is a full-time board-certified hair restoration physician who has treated over 33,000 patients and performed over 12,000 hair transplant procedures. He is the founder of Bauman Medical, a state-of-the-art hair restoration clinic in Boca Raton, Florida.Dr. Bauman is known for pioneering numerous technologies in the field of hair restoration, including minimally invasive FUE hair transplants, low-level laser therapy, PRP, PDO threads, and scalp makeovers. He's been voted "#1 Top Hair Restoration Surgeon" in North America and was recently recognized by Forbes as one of the "10 CEOs Transforming Healthcare in America."Dr. Bauman received his medical degree from New York Medical College and completed his residency training at Mt. Sinai Medical Center and Beth Israel Medical Center. A hair loss sufferer himself, he has dedicated his career to helping patients navigate their hair restoration journey with compassion and cutting-edge care.Resources:-  Discover the groundbreaking ESS60 molecule, proven to extend life by 90%, at MyVitalC.comConnect with Dr. Alan Bauman- Website: https://www.baumanmedical.com/ - LinkedIn: https://www.linkedin.com/in/alanjbauman/ Connect with Christopher Burres- Website - https://www.myvitalc.com/- Website - https://www.livebeyondthenorms.com/- Instagram - https://www.instagram.com/chrisburres/- TikTok - https://www.tiktok.com/@myvitalc - LinkedIn - https://www.linkedin.com/in/chrisburres/ /

In this CME episode, Dr. Andy Cutler interviews Dr. Leslie Citrome about the impact of tardive dyskinesia on patient-reported outcomes and quality of life. They discuss how to correctly assess and diagnose tardive dyskinesia, as well as effective management strategies that incorporate the individual needs of patients.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Understand the physical, psychological, social, and occupational impacts of tardive dyskinesia (TD) on patients Identify clinical tools and patient-reported outcome measures to assess the severity and impact of TD Formulate evidence-based treatment strategies for TD that enhance patient outcomes and quality of life Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.   Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour Released: October 23, 2024*   Expiration: October 22, 2027 *NEI maintains a record of participation for six (6) years.   CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-TD   Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hour Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until OCtober 22, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Leslie Citrome, MD, MPH Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY Consultant/Advisor: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Delpor, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Luye, Lyndra, MapLight, Marvin, Medavante-ProPhase, Merck, Mitsubishi-Tanabe Pharma, Neumora, Neurocrine, Neurelis, Noema, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sumitomo/Sunovion, Supernus, Teva, University of Arizona, Vanda Speakers Bureau: AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva Stockholder: Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer, Reviva (options) The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, CHCP, and Brielle Calleo. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an unrestricted educational grant from Teva Pharmaceuticals.

Traditional Chinese Medicine (TCM) uses biological extracts to treat disease. Eczema sufferers may take a herbal bath, apply a specially formulated cream or drink herbal tea as part of TCM treatment. Dr. Xiu Min Li from New York Medical College explains TCM and we ask: Is Traditional Chinese Medicine (TCM) safe for newborns? Can you use TCM and topical steroids simultaneously? Could TCM prevent the allergic march? Research mentionedInvestigation of Berberine's Potential in Attenuating Staphylococcus aureus-Induced Inflammatory ResponsesInvestigation of In vitro Anti-inflammatory and Antimicrobial Effects of BerberineEffect of Traditional Chinese Medicine (TCM) in moderate-to-severe eczema in clinic and animal model: beyond corticosteroidsTraditional Chinese medicine for food allergy and eczemaEffect of traditional Chinese medicine on skin lesions and quality of life in patients with moderate to severe eczemaEfficacy and safety of Chinese herbal medicine for atopic dermatitis: Evidence from eight high-quality randomized placebo-controlled trials.

Check out Dr. Mina's top picks for skin care here. Download the free eBook 'Skincare Myths Busted' here. If you've explored the world of fillers, you've probably come across hyaluronic acid options like Juvederm and Restylane. It's no surprise they're a favorite—they provide instant results, helping to restore volume and define facial contours. But what if I told you there's another approach to skincare that, while it takes a little more time, delivers longer-lasting and more natural-looking results? Welcome to the world of biostimulants! Check out this week's podcast with Dr. Sapna Palep, where she explains what biostimulants are, the science behind how they work, and the amazing benefits they offer for skin regeneration and overall health! Key Takeaways: - Biostimulants stimulate collagen production over time. - Fillers provide immediate results but are not long-lasting. - A global approach to facial aesthetics is essential. - Patience is key when using biostimulants. - Simplified skincare routines can save money in the long run. - Word of mouth referrals are important for finding providers. - Biostimulants can be used in various areas beyond the face. - Combining treatments can yield optimal results. - Understanding the differences between fillers and biostimulants is crucial. - Education is vital for patients navigating skincare options. Dr. Sapna Palep has been recognized as one of New York's leading board-certified dermatologists for over a decade. Since founding Spring Street Dermatology in 2010, Dr. Palep has helped countless patients achieve clear, healthy skin with her safe, effective, and highly individualized treatment plans. Dr. Palep conducts annual skin cancer screenings and treats all dermatologic conditions, including acne, eczema, psoriasis, and rosacea. She is also highly sought after for her skill in cosmetic treatments, including Botox, chemical peels, dermal fillers, microneedling, and resurfacing lasers. A native of Florida, Dr. Palep completed her undergraduate studies in biology and chemistry at the University of Miami in 1999. She attended the University of Miami School of Medicine for two years before relocating to New York in 2000. She completed her medical degree at New York Medical College in 2004. The same year, Dr. Palep graduated with a Master's of Business Administration from the Lubin School of Business at Pace University, where she majored in Health Systems Management. After an internship in internal medicine at Soundshore Medical Center in New Rochelle, Dr. Palep began her residency in dermatology at Mount Sinai Medical Center in 2006. She served as Chief Resident in the department of Dermatology from 2008 to 2009. Since 2010, Dr. Palep has served as Associate Clinical Professor, in the department of Dermatology at the Icahn School of Medicine at Mount Sinai Hospital. For her commitment to excellence in education, Dr. Palep was presented with the Teacher of the Year Award in 2010 and 2012, and the Mentor of the Year Award in 2013. In 2015, the Leading Physicians of the World recognized Dr. Palep as a Top Dermatologist in New York. Castle Connolly has named Dr. Palep a Top Doctor in the New York Metro Area consecutively since 2018. Dr. Palep has conducted extensive research in medical dermatology, with a focus on the carcinogenic effects of UV radiation on DNA. Her work has been published in the Journal of the American Association of Dermatology, the Journal of Cutaneous Pathology, and the Journal of Investigative Dermatology. Dr. Palep is an active member of the American Medical Association, the American Medical Women's Association, the American Academy of Dermatology, the New York Academy of Medicine, the New York Dermatology Society, and the Society of Investigative Dermatology. Find Dr. Sapna Palep here: Website: www.springstderm.com https://www.instagram.com/springstreetdermatology/?hl=en https://www.instagram.com/drsapnapalep/?hl=en Follow Dr. Mina here:- https://instagram.com/drminaskin https://www.facebook.com/drminaskin https://www.youtube.com/@drminaskin https://www.linkedin.com/in/drminaskin/ For more great skin care tips, subscribe to The Skin Real Podcast or visit www.theskinreal.com Baucom & Mina Derm Surgery, LLC Email - scheduling@atlantadermsurgery.com Contact - (404) 844-0496 Instagram - https://www.instagram.com/baucomminamd/ Thanks for listening! The content of this podcast is for entertainment, educational, and informational purposes and does not constitute formal medical advice.

This episode's Community Champion Sponsor is Ossur. To learn more about their ‘Responsible for Tomorrow' Sustainability Campaign, and how you can get involved: CLICK HERE---Episode Overview: How can healthcare systems leverage innovation to provide equitable access to high-quality care across diverse communities? Our next guest, Dr. JP Valin, is spearheading this mission as Chief Clinical Officer of Intermountain Health. With deep clinical experience and a passion for connecting fragmented healthcare, Dr. Valin brings a unique perspective to addressing industry-wide challenges. As the leader of clinical operations for one of the nation's top healthcare enterprises, he's driving initiatives to combat workforce shortages, harness AI's potential, and activate patients in their health journeys. While together, Dr. Valin and I explore how Intermountain Health is reimagining care delivery across urban and rural settings, embracing technology to enhance clinician efficiency, and pioneering innovative solutions to create healthier communities. Join us as Dr. Valin shares his vision for a future where personalized, accessible care is the norm. Let's go!Episode Highlights:Addressing the critical healthcare workforce shortage and revealing that a third of Intermountain Health's physicians and APPs will retire by the end of the decadeEmphasizing the importance of leveraging technology to expand care delivery beyond traditional one-on-one doctor-patient relationshipsImplementing innovative tools like ambient listening and AI to increase clinician efficiency and reduce non-value-added workThe potential of Large Language Models (LLMs) to personalize patient care by synthesizing vast amounts of medical research and dataActivating patients as key partners in their own healthcare journey, focusing on healthy behaviors between clinical visitsAbout our Guest: Dr. JP Valin was named Intermountain Health's Chief Clinical Officer (CCO) in 2022 immediately following the organization's merger with SCL Health. As CCO, he is responsible for leading clinical operations across the enterprise to improve equitable access to the highest quality care for patients and communities.Dr. Valin graduated from Georgetown University and New York Medical College, and he holds a master's in healthcare administration from the Health Management Academy/University of Providence.In addition to serving in various leadership positions, Dr. Valin also practiced clinically for 15years as both a full scope general internist and a full-time hospitalist.Dr. Valin received the Clinician Experience Project's CEO Award of Excellence in December 2020 as well as a special recognition from the Leapfrog Group for Pandemic Heroism. In August 2021 he received Huron's What's Right in Health Care® Hero Award. And most recently, Dr. Valin was named as one of Becker's Healthcare's 2023 Chief Medical Officers to Know.Links Supporting This Episode:Intermountain Health Website: CLICK HEREDr. JP Valin LinkedIn page: CLICK HEREIntermountain Health LinkedIn page: CLICK HERE Mike Biselli LinkedIn page: CLICK HEREMike Biselli Twitter page:

ACCME President and CEO Graham McMahon, MD, MMSc, welcomes Dr. Kristina H. Petersen to the podcast for a discussion about accessibility in healthcare and healthcare continung education. Formerly of New York Medical College, Dr. Kristina H. Petersen is now Assistant Dean of Student Success & Access and Associate Professor of Biochemistry & Molecular Biophysics at Washington University in St. Louis School of Medicine. Her scholarly work primarily focuses on inclusive instruction, course and assessment accessibility, and creating curriculum to teach clinicians about persons with disabilities. In 2022, she received an award for Excellence in Scholarly Work from the Coalition for Disability Access in Health Science Education and the AAMC/Alpha Omega Alpha Robert J. Glaser Distinguished Teaching Award. She is currently an Alpha Omega Alpha Fellow in Leadership.

Join us for an insightful episode of "Restful Recovery," where we explore the crucial interplay between sleep and cancer with Dr. Daniel Barone, a leading expert in sleep medicine. Dr. Barone, the Associate Medical Director at the Weill Cornell Center for Sleep Medicine, shares his extensive knowledge and experience in the field, offering valuable guidance on how sleep impacts cancer treatment and recovery. Dr. Barone's illustrious career began with his summa cum laude graduation from Fordham University, followed by his medical degree from New York Medical College. His path included an internship in Internal Medicine at Saint Vincent's Catholic Medical Center, and subsequent Neurology training, where he was named Chief Resident. He completed his Neurology residency at Beth Israel Medical Center and a fellowship in Sleep Disorders at Stony Brook University Medical Center. As an Associate Professor of Clinical Neurology at Weill Cornell Medical College and an Attending Neurologist at NewYork-Presbyterian/Weill Cornell Medical Center, Dr. Barone specializes in managing various sleep disorders, including sleep apnea, insomnia, and restless legs syndrome. His certifications and affiliations, including those with the American Academy of Neurology and the American Academy of Sleep Medicine, underscore his expertise. In this episode, Dr. Barone discusses how sleep affects cancer patients, strategies for improving sleep during treatment, and the latest research findings. His insights are drawn from his peer-reviewed publications, media appearances, and his books, "Let's Talk About Sleep" and "The Story of Sleep: From A to Zzz." Tune in to learn how better sleep can be a powerful ally in cancer care and recovery, and gain practical tips for improving your sleep health during challenging times. --- Support this podcast: https://podcasters.spotify.com/pod/show/aimatmelanoma/support

In a world where we're expected to mask our struggles behind a white coat or a suit, finding the courage to be an open book is truly commendable. We all have struggles and setbacks in different forms. Some of us face challenges in our careers, others deal with personal issues, and many of us encounter both at the same time. Whether it's grappling with addiction, experiencing job loss, or dealing with health crises, the journey through these trials can be incredibly tough.    Many of us compartmentalize our pain until it overwhelms us, but acknowledging our challenges is the first step towards healing. When we begin to openly recognize and talk about our difficulties, we take a significant step toward recovery. Embracing this openness allows us to seek the support we need from mentors, coaches, and loved ones. By sharing our experiences and vulnerabilities, we break down the walls of isolation and build connections with others who may have faced similar struggles and provide them with grace we have received.Remember, it's through understanding our struggles and reaching out for support that we transform our challenges into strengths.    Courtney Barrows McKeown, MD is a board-certified general surgeon. She earned her medical degree at New York Medical College, graduating Alpha Omega Alpha. She completed her general surgery residency training in 2020 at Beth Israel Deaconess Medical Center in Boston, MA, and received additional subspecialty training in hepatopancreatobiliary (HPB surgery) in the Midwest. She started her career as a community general surgeon in New Hampshire, and is excited for her next opportunity, where she will be moving to TN to join Dr. Vertrees' Columbia Surgical Partners as a general surgeon. Her mission is to provide hope and mentorship to other early career physicians who may be struggling with similar issues she faced, reduce stigma, and help drive systemic changes in order to make our professional climate better for the next generation of surgeons.   In this episode with Dr. Courtney Barrows McKeown, we will learn about the power of resilience, the importance of seeking help, and the value of mentorship in overcoming personal and professional challenges. Dr. McKeown openly discusses the difficulties of dealing with addiction, especially in a high-pressure profession like surgery. Her honesty about her struggles is both courageous and inspiring, shedding light on the often-hidden challenges faced by many professionals. Dr. McKeown's story is a beacon of hope, showing that with perseverance and the right support, we can overcome even the most daunting obstacles.    "It's not my fault that I have a disease, but it is my responsibility to get it treated and then manage it." –  Dr. Courtney Barrows McKeown   Topics Covered: (00:00:34) Introducing our special guest, Dr. Courtney Barrows McKeown (00:02:56) Hitting rock bottom (00:04:01) How acceptance and accountability change Dr. Courtney for the better (00:06:03) Career opportunity through coaching connections (00:08:52) The silent struggles of medical professionals (00:10:37) The value of coaching for physicians (00:13:00) An overcomer by the grace of God (00:17:12) How Dr. Courtney's med school stress sparked a struggle with addiction (00:21:38) Advertisement: Are you prepared for life's unexpected challenges? Dr. Stephanie Pearson and her team of skilled advisors at Pearson Ravitz are here to help you guard your most valuable asset. Go to https://pearsonravitz.com/ to make sure you are protected today. (00:22:28) Who was able to help you get help?  (00:25:23) How compassion made healing possible (00:27:12) Prevalence of mental health issues in healthcare (00:29:50) Embracing a new beginning (00:34:03) The role of patience and timing in career success (00:37:06) The Final TimeOut: Jeremiah 29:11 (00:39:02) Where to connect to  Dr. Courtney Barrows McKeown (00:21:49)    Key Takeaways:    "The problem with social media and being a doctor is that many times we feel that we have to struggle alone."– Dr. Derrick Burgess   "We've learned to compartmentalize our struggles and show up for everyone else, ignoring our own problems until they come back to destroy us."– Dr. Derrick Burgess   "You are not your struggles, you are not your addiction, you are not whatever you struggled with. It doesn't define you."– Dr. Derrick Burgess   "You do the best you can until you know better, and then when you know better, do better."–  Dr. Courtney Barrows McKeown   "Just like athletes need coaches to perform at their peak ability, anybody else from a lawyer, a physician, we need coaching as well."– Dr. Derrick Burgess   “Having all of those people behind me to help, I can't take much credit honestly, other than just kind of being willing to move forward and not give up.” –  Dr. Courtney Barrows McKeown   “Just because someone shows up to work every day and is able to perform from 6 to 5 or 6 to 9, doesn't mean that they're ok.” – Dr. Derrick Burgess   “It's ok to cry for both good and sad reasons.” –  Dr. Courtney Barrows McKeown   Connect with Dr. Courtney Barrows McKeown: Facebook: https://www.facebook.com/courtney.barrows Instagram: https://www.instagram.com/courtb_mckeown_md LinkedIn: https://www.linkedin.com/in/courtney-barrows-mckeown-md/    Connect with Dr. Derrick Burgess: Website: https://www.drderrickthesportsdr.com/ Instagram: https://www.instagram.com/drderrickthesportsdr/ Facebook: https://www.facebook.com/TimeOut.SportsDr LinkedIn: https://www.linkedin.com/in/derrick-burgess-72047b246/ YouTube: https://www.youtube.com/channel/UCHGDu1zT4K_X6PnYELu8weg Email: thesportsdoctr@gmail.com   This episode of TimeOut with the SportsDr. is produced by Podcast VAs Philippines - the team that helps podcasters effectively launch and manage their podcasts, so we don't have to. Record, share, and repeat! Podcast VAs PH gives me back my time so I can focus on the core functions of my business. Need expert help with your podcast? Go to www.podcastvasph.com.

As a runner, it's almost guaranteed that somebody has told you, "Running is bad for your knees!" Spoiler alert: It's not. Dr. Howard Luks has the education and experience to prove it. Howard spent more than 20 years as the Chief of Sports Medicine and Arthroscopy at New York Medical College, specializing in athlete care. As a board certified orthopedic surgeon, he focuses on a variety of joints but focuses on knee health. In this episode, Howard and I talk about: Squats for knee health: form and variety Functional strength training that mimics life activities Assessing risk with knee pain or swelling, and whether you should stop running The true cause of osteoarthritis How running can actually help knee health and cartilage Running types that put runners at higher risk for knee injury Managing knee injuries through load management and smart exercises Exercises to improve power and quickness for running on hills and trails The effects of shoe choice and training surface Next time somebody tells you that running will hurt your knees, send them this episode. Links & Resources from the Show: Howard on Twitter/X Howard on Instagram Read Howard's book, "Longevity… Simplified" Injury prone? Download our free Little Black Book of Recovery & Prevention featuring 9 pro runners and their strategies for recovering and staying healthy. Thank you Previnex! After resisting most supplements for the better part of my life, I'm cautiously changing my tune. I'm now a Masters runner and in my personal life, I'm optimizing for longevity. I want to be my healthiest self for as long as possible and I'm excited to partner with Previnex to make that happen. Previnex uses the most bioavailable, clinically tested ingredients, the optimal form and dose of each ingredient, pharmaceutical grade manufacturing, testing of raw ingredients and finished products. For every purchase you make, they also donate vitamins to kids in need. Their new Muscle Health Plus is something I'm now taking. Turning 40 - and having a thin frame - has made me realize that I need to prioritize lean muscle mass to stay healthy and age well. Muscle Health Plus has creatine, essential and branched chain amino acids, and it's designed in a way to maximize protein synthesis and the absorption of amino acids. Muscle Health Plus will help you prevent muscle damage, which is particularly important for aging runners who want to protect themselves from muscle loss and recover faster after hard workouts. As is true for all of their products, Previnex adheres to the highest of standards: their ingredients are clinically proven to do what they say they're going to do. Previnex offers a 30-day money back guarantee. If you don't feel the benefits of their product, you get your money back no questions asked. With their focus on quality and customer satisfaction, I hope you'll try it! Use code jason15 for 15% off your first order at Previnex! Thank you AG1! We're also supported by AG1, the greens superfood mix. This is a category-leading greens mix that has 75 vitamins and minerals, prebiotics, probiotics, antioxidants, and adaptogens. It's recommended by professional athletes and has over 7,000 positive reviews. One scoop per day is what I've been doing to help me fill in any nutrition gaps in my diet. It also provide a nice boost of energy and focus throughout the day. With all 3 of my kids in school, I know I need to support my immune system or else I'm getting sick and can't train. I also love that AG1 has changed over the last decade. They've made 53 improvements to the formula based on the latest research to make these nutrients more absorbable and rigorous with the 3rd party testing that they do. For our listeners, they are offering a year's worth of free Vitamin D and 5 free travel packs of AG1 with your first purchase. You can sign up for single shipment or for a monthly drop – the choice is yours. Check out AG1 to redeem your offer today.  

This week it is a pleasure to welcome developmental pediatrician Dr. Mark Bertin to The Hamilton Review Podcast! In this important conversation, Dr. Mark Bertin discusses the following:   - Mindfulness (mindfulness is seeing things as clearly as possible) in ADHD. - All of the evidenced based information on ADHD. - ADHD is a developmental disorder of executive function and how to help our kids navigate through it successfully and become independent. - Mindfulness and resilience and how it can be a useful part of parenting. A critical episode for all parents dealing with children who have ADHD.  Dr. Bertin is a developmental pediatrician and author of How Children Thrive, Mindful Parenting for ADHD, Mindfulness and Self-Compassion for Teen ADHD and The Family ADHD Solution, all of which integrate mindfulness into the rest pediatric care, and a contributing author for the book Teaching Mindfulness Skills to Kids and Teens.   Dr. Bertin is a faculty member at New York Medical College and the Windward Teacher Training Institute and has served on advisory boards for APSARD, Additude Magazine, Common Sense Media and Reach Out and Read.   His blog is available through Psychology Today and elsewhere. For more information, please visit his website at www.developmentaldoctor.com.   How to contact Dr. Mark Bertin: Dr. Mark Bertin website   How to contact Dr. Bob: Dr. Bob on YouTube: https://www.youtube.com/channel/UChztMVtPCLJkiXvv7H5tpDQ Dr. Bob on Instagram: https://www.instagram.com/drroberthamilton/ Dr. Bob on Facebook: https://www.facebook.com/bob.hamilton.1656 Dr. Bob's Seven Secrets Of The Newborn website: https://7secretsofthenewborn.com/ Dr. Bob's website: https://roberthamiltonmd.com/ Pacific Ocean Pediatrics: http://www.pacificoceanpediatrics.com/

JCO PO author Dr. Jun Gong shares insights into his JCO PO articles, “Phase II Study of Erdafitinib in Patients with Tumors with FGFR Amplifications: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol K1" and “Phase II Study of Erdafitinib in Patients with Tumors with FGFR Mutations or Fusions: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol K2”. Host Dr. Rafeh Naqash and Dr. Gong discuss the limited activity of FGFR inhibition in solid tumors with FGFR amplifications and mutations or fusions in this NCI-MATCH phase II trial. TRANSCRIPT  Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, Social Media Editor for JCO Precision Oncology and Assistant Professor at the Stevenson Cancer Center at the University of Oklahoma.  Today, we are excited to be joined by Dr. Jun Gong, Associate Professor in the Division of Medical Oncology at Cedars-Sinai Medical Center and lead author of the JCO Precision Oncology article entitled "Phase II Study of Erdafitinib in Patients with Tumors Harboring FGFR Amplifications: Results from the NCI-MATCH ECOG-ACRIN Trial EAY131 Subprotocol K1" and "Phase II Study of Erdafitinib in Patients with Tumors with FGFR Mutations or Fusions: Results from the NCI-MATCH ECOG-ACRIN Trial EAY131 Subprotocol K2."   Our guest's disclosures will be linked in the transcript.   Dr. Gong, welcome to our podcast and thank you for joining us.  Dr. Jun Gong: Thank you, Dr. Naqash and JCO Precision Oncology for having me. Dr. Rafeh Naqash: We are excited to be discussing some interesting aspects that you have led and published on from the NCI-MATCH trial. We were trying to understand from a background perspective, since this master protocol has been going on for quite some time, could you give us a little bit of background for the sake of our listeners on what the NCI-MATCH is and what were the specific objectives for these two subprotocols?  Dr. Jun Gong: Yes, of course, Dr. Naqash. So, as you may all know, the importance of targeted therapies in the current era of precision oncology. And on that backdrop, the NCI-MATCH was a national multicenter study designed essentially to look for signals of efficacy across various solid tumor and hematologic malignancy types, with a focus on specific mutations. The master protocol is unique in that there are several arms to the trial, each targeting a specific potential targetable alteration using available agents in cancer today. Dr. Rafeh Naqash: Excellent. Thank you for that background. I know this master protocol has been going on for quite some time with different subprotocols. I believe some of them are immunotherapy-based. Also, you've led two important subprotocols, which are the FGFR amplification and the FGFR mutation or fusion. There are some differences, from what I gather, in responses for the fusions versus the amplifications or mutations versus the amplifications. Could you first delve into the first paper of the fusions, and describe what were the tumor types? As you mentioned in the paper, some tumors were excluded. What was the reason for the exclusion of some of those tumor types? Why did you want to study the fusions and mutations versus the amplifications separately? What was the background for that? Could you highlight some of those points for us? Dr. Jun Gong: Firstly, as a kind of a more background, FGFR has been a recognizable target for a couple of tumor types. And if you look at the broad landscape of FGFR alterations, they occur in about 5%-10% of cancers, with the majority being FGFR amplifications actually, and mutations and rearrangements following second and third respectively in most commonly identified alterations. With that being said, FGFR mutations and rearrangements have already been established in a couple of tumor types. Actually, the first FDA approval for an oral FGFR inhibitor was erdafitinib, which was the agent used in both of these back-to-back trials. However, erdafitinib was first approved in urothelial carcinoma, and since then, there has been an explosion in oral FGFR inhibitors targeting fusions and mutations in other cancer types, such as cholangiocarcinoma.   More recently, there was even an FDA approval in a myeloid malignancy as well. So, we used erdafitinib, being that it was the first FDA-approved, orally available agent to target this alteration. We conducted the two back-to-back studies in recognition that although rearrangements and mutations have already been established in certain tumor types, we were more interested in looking at the more common FGFR alteration, that being amplifications. However, the efficacy in that was a little unknown, and so these two separate subprotocols were developed: K2, which was to look at FGFR mutations and fusions in tumor types, excluding urothelial carcinoma, to look if there was a signal of efficacy beyond currently FDA-approved indications, and amplification as a separate cohort. Dr. Rafeh Naqash: That's a very good explanation of why you concentrated on the tumor types in these protocols.  Now, going back to subprotocol K1, could you tell us what were some of the tumor types that you did include, and what was the sample size, and what was the hypothesis for the sample size as a meaningful level of activity that you wanted to see and would have potentially led to a bigger, broader trial? Dr. Jun Gong: So, subprotocol K1 was the arm investigating erdafitinib in those with FGFR amplifications, and these were predefined on the NCI-MATCH protocol, looking at FGFR 1, 2, 3, and 4 amplifications essentially. These were allowed to have local testing through a local CLIA-certified assay, but then they needed to be confirmed on a central assay, which is the NCI-MATCH Oncomine assay. These statistics are uniform for the NCI-MATCH trials, and the goal was at least 31 patients, with the hypothesis that if the response rate was 16% or more, this was considered a signal of activity. However, there was an additional protocol specific requirement in that if the sample size was fewer than 31 patients, then the primary efficacy population would be assessed against a null hypothesis overall response rate of 5%. Meaning that if there were less than 31 subjects, an overall response rate of greater than 5% would be defined as positive. Again, the NCI-MATCH was uniform. Secondary objectives included progression-free survival, overall survival, and safety and toxicity. With that being said, K1 originally began accrual. The NCI-MATCH actually launched in 2015, but in the subprotocol K1, 35 patients were initially enrolled in the study. If you go down the eligibility criteria, however, a lot of these patients dropped out due to a lack of central tumor confirmation and various reasons. Ultimately, 18 patients were included in the pre-specified primary efficacy cohort. Dr. Rafeh Naqash: Thank you. I did see for subprotocol K1, you mostly had stable disease in a couple of patients, no responses, and I think one individual with breast cancer had a prolonged stable disease.   Now, from an FGFR amplification standpoint, did you or were you able to correlate - again, this is not objective responses, it's not a partial response or a complete response - was there any correlation from the level of amplification to the duration of stable disease?  Dr. Jun Gong: That's actually the core of our discussion about why K1, despite a variety basket of solid tumor types, somewhere, preclinical data had suggested FGFR amplifications could be targeted, that K1 was ultimately a negative trial with a 0% response rate. We dive in that although we included as an eligibility criteria a copy number variation of seven as the threshold for amplification, we realized that if you look at some of the literature out there, that even in the FGFR 1 and 2 amplification cohorts, where these are the more common cohorts of amplified tumor types that have been targeted, you really needed a high level of amplification, more than 99% of tumor cells being amplified in the previous studies, to actually generate a response.  The thought was that we assumed that FGFR amplification would lead to protein expression and dependence on FGFR signaling, providing sensitivity to FGFR inhibition. However, we realized that there is a certain degree where a high level of amplification needs to happen, and it may not be for all FGFR amplifications. We looked into the literature that FGFR 1 and 2 were the more commonly studied FGFR amplifications. FGFR 1, if you actually look at the amplicon structure, it tends to amplify a lot of other genes because it's such a huge amplicon structure. But FGFR 2 is shorter and centered on just FGFR 2 with a few other genes co-amplified. So, actually in the literature, they've already been seeing that maybe FGFR 2 amplification tumors are more readily targetable based on the robustness of evidence, rather than FGFR 1. But across all of these, the higher the level of amplification, seems the more targetable. Dr. Rafeh Naqash: Those are interesting discussions around protein expression on the tumor that could imply therapeutic vulnerability. So I've always thought about it, whether trials like NCI-MATCH trials or ASCO TAPUR, for example, would be perhaps more informative if, on a secondary analysis standpoint, proteomics is something that could be done on the tumor tissue, because similar to NCI-MATCH, ASCO TAPUR has other sub protocols where some of these mutations or amplifications don't necessarily result in antitumor responses. But I think from a biology standpoint, as you mentioned, a certain amplification might correspond to RNA expression and that might correspond to protein expression, which is downstream. So looking at that would be something interesting. Have you planned for something like that on these tumor specimens? If you have biobanked any of those specimens. Dr. Jun Gong: I think that's a great future direction. And I know you, Dr. Naqash, being involved in so many cooperative trials, I think it is possible, but it really depends on good trial planning from the onset. When designing such massive trials like this, I think the more important thing is if your trials are negative, but they are informative for the field to go back and have these postdoc available biobanks that you said. And I think having it integrated firstly, is way more efficient than to have kind of an amendment kind of going through halfway or when the trial is started. That could be a little bit more logistically difficult.  Dr. Rafeh Naqash: I completely agree. And you mentioned corporate groups, I think we've been discussing, and I'm pretty sure you have also, there's a lot to be learned from clinical trials that are negative. We often, in the academic or non-academic setting, end up not publishing some of those negative results, pharma or corporate group based studies. And I think the resources, the specimens, and the negative results could correlate to some other novel findings if some of those exploratory analyses are done in the appropriate manner.   Now, going to the drug itself or the erdafitinib here, it's a pan-FGFR inhibitor. Is that something that you think is a limitation in the drug development space? I do early phase trials, and I'm pretty sure you do a lot of these basket early phase trials. Is that something that you feel is a limitation when you have a drug that targets different mutations or different protein changes of the same gene or different amplifications? Could that be a reason why something like this doesn't necessarily work because it doesn't have as much specificity against the isoform as one might need to inhibit the downstream kinase activation?  Dr. Jun Gong: That is also a great point. The NCI-MATCH sub protocol K1 and K2 used erdafitinib, which was the first FDA-approved FGFR inhibitor. But as many of the listeners and yourself may know, there have been newer iterations in next-generation development of the FGFR inhibitors. And it's very fascinating, the tyrosine kinase inhibitors, with each iteration, you seem to have a little more potency and the ability to bypass some of the resistance mutations, almost paralleling the lung cancer space, where we kind of follow that, and they've been kind of the pioneers in that space. And to your point, yes, we consider– the NCI-MATCH was developed nearly a decade ago, and the available agents at that time, would it have changed the findings if we used a kind of a newer generation or more potent FGFR inhibitor? It's possible, I think, especially in the K1 cohort with the amplifications. We even suggested in the discussion of the paper future directions, is that one way to kind of bypass the amplification issue is to use more potent and specific FGFR inhibitors. And so I think it's very possible that you highlight this point.  Dr. Rafeh Naqash: And for the sake of our listeners, Jun, especially trainees, could you highlight what are currently some of the FDA-approved FGFR inhibitors, and what tumor types are they currently approved in?  Dr. Jun Gong: The first one, as we have hinted, was in treatment of refractory, essentially urothelial carcinoma with FGFR mutations and rearrangements, mainly 2 and 3. And this is where oral erdafitinib was approved. And it's interesting, I kind of teach my fellows and our health staff that erdafitinib is interesting in that its FDA label insert requires a starting dose of about 8 milligrams daily, and it's a 28-day cycle. But during the first 14 days, we're really looking at the serum phosphate levels. If they are within a certain level, if they are within 5.5 to 7, for example, you continue the current dose. But if they are less than 5.5, the FDA label actually mandates that you increase it to 9 milligrams oral daily, continuously. This is biologically logical to me. FGFR is located to the renal tubules, and so this is a major phosphate kind of metabolism pathway here. And so you're using that as a surrogate, essentially, if the right dosing is achieved. And so that's unique.  And then the subsequent kind of FGFR inhibitors that came about, you had a couple in cholangiocarcinoma, where, unlike urothelial carcinoma, where it's about 30% of the time, you'll find the FGFR alterations of target. It's about half of that 15% in cholangiocarcinoma, and it's mainly intrahepatic cholangiocarcinoma in that sense. And here you have pemigatinib, which is one of the FGFR inhibitors approved for cholangiocarcinoma. And then you also had infragatinib, which is approved. But however, infigratinib eventually had their FDA label culled. It was withdrawn by the company, I think it was in 2022. And then more recently, you had even a more potent FGFR inhibitor in cholangio approved and futibatinib. It's interesting that with these more later generations of FGFR inhibitors, they do show a correlation with phosphate levels, but they don't have that specific kind of dosing early on in the first cycle, like erdafitinib. And so it's interesting to see that with the later generations, you're seeing more potency as well. Dr. Rafeh Naqash: Thank you for that overview, which I'm sure most of the trainees appreciate since this is an up and coming field in the space of precision medicine, especially FGFR. From a side-effect profile standpoint, you mentioned phosphate issues. Do you think that is a drug class effect here, or is that an FGFR receptor subtype effect, depending on which FGFR receptor, 1 or 2 or 3, that is being targeted?  Dr. Jun Gong: I do think this is a class effect that you'll see across a lot of the trials where phosphorus elevations or decreases are going to be probably your most common treatment-related adverse event. And I actually emphasize this is probably one of the most trickier side effects of this class, where we're almost having to have to monitor the phosphorus levels pretty routinely, pretty closely. And you also have other class effects on the nails. There's some rare retinal ocular toxicities that's unique to the FGFR class as well. And so it's a very exciting class of compounds, but it does require some close monitoring of some unique class effects as you've hinted. Dr. Rafeh Naqash: Based on the results from your K1 sub protocol, are FGFR inhibitors still the approach within, let's say, within cholangio or urothelial with FGFR amplifications? Is that still something that has been established and seen from a clinical response standpoint? Dr. Jun Gong: The FDA approvals are really for mutations and fusions. So this K1 sub protocol, essentially, I think provides one answer that we've been all wondering about for the longest time, “Hey, could amplifications be targeted as well?” Unfortunately, we didn't include urothelial carcinomas in this study because of the FDA approval. But from a kind of a basket solid tumor perspective, I think this really dampens the enthusiasm. As of right now, it really is fusions and mutations that are targetable. Amplifications need further investigation before becoming established in solid tumors. Dr. Rafeh Naqash: Going to the discussion with the second K2 protocol, which is mutations and fusions, can you highlight again which tumor types there where you saw some clinical outcomes that you saw and any unique insights on certain mutations or protein changes that were a little more relevant than some others?  Dr. Jun Gong: Sure. So this is the parallel study to K1, in that now we are looking at fusions and mutations of FGFR1, 2, 3, and 4. And essentially, we, again, excluded those with urothelial carcinoma, given the FDA approval for erdafitinib in this trial. The trial actually opened then the FDA approvals for the FGFR inhibitors for cholangiocarcinoma happened. So this trial didn't really exclude those with FGFR mutated or rearranged cholangiocarcinoma as well. If you look at the breakdown of the cohort in K2, you saw a good mix of breast cancers or a couple of gynecologic malignancies. There were a couple of head and neck cancers. There were several brain tumors as well. There was one lung cancer. There were four noted intrahepatic cholangiocarcinomas. Again, we could not exclude those due to the fact that the trial had opened and was accruing when the FGFR inhibitors approved for cholangiocarcinoma happened. Similar design, with a phase II, single-arm, open-label of erdafitinib, and again, the same statistical design was implemented in that if it's higher than 31 patients, 16% overall response rate was a primary endpoint goal. If it was less than that, it was against the 5% overall response rate.   And here in K2, 35 patients were enrolled and 25 patients were ultimately included in the primary efficacy analysis. So because it was fewer than 31 in the primary efficacy cohort, it followed the NCI-MATCH to be specified with a primary endpoint goal of 5% or higher. And here, in a heavily pre-treated cohort of more than 50% of subjects who have received prior than 3 or higher lines of therapy, overall response rate essentially confirmed was 16% with the p value of 0.034, which met the positivity cutoff of 5%. However, an additional seven patients experienced stable disease as best confirmed response. And it's important to note that four of these were grade IV glioblastomas with prolonged progression-free survival. So ultimately, this trial was positive in reading the endpoint that outside of urothelial carcinoma, could FGFR inhibition be pursued in other tumor types that had FGFR rearrangements or fusions? Dr. Rafeh Naqash: You mentioned glioblastoma, which is an area of huge unmet need. Do you think a trial like this as an upfront approach in glioblastoma, perhaps maybe after Temodar, could be a more meaningful way using the strongest, more precise therapy earlier on when there are certain mechanisms that inhibition of which would result in anti-tumor responses? Do you think doing this earlier on rather than second, third, fourth line would be more intriguing in some ways?  Dr. Jun Gong: I think you've hit upon several key points there. Firstly, just a high unmet need in glioblastomas, in general. And then to us, although it was a stable disease it was quite noticeable that four of these occurred in IDH1 and 2 wild-type brain tumors. We kind of discussed that in the discussion as well. And of these, we actually realized that in the pre-clinical and other published literatures space that for some reason, IDH1 and wild-type tended to have more FGFR alterations, while 0% were found in IDH1 and 2 mutant high grade gliomas. So I think there is something hypothesis generating coming out of this study as well even though there were stable disease. And that you may be selecting for– We may be able to have future studies to select for a specific niche of glioblastomas. And as to your point, Dr. Naqash, I think  if we can have a design trial looking for these specific molecular subsets, I think it's wide open for trials of this nature in the first line, second line, or refractory space. Even piggybacking into cholangiocarcinoma, you see, they're now looking at these in the neoadjuvant and adjuvant space as well. So I think we can identify the subset - it's wide open out there. Dr. Rafeh Naqash: I completely agree. I remember my program director a few years back when immunotherapy was in the metastatic setting, it was very exciting. He gave a talk in which he said "Early, earlier, earliest," and the more early, the better it seems. So I'm guessing that it's probably something similar for precision medicine-based approaches like targeting FGFR perhaps earlier.   So what is next for some of these two studies, or these ideas that have come out of these two studies? Are you trying to develop something subsequently, or is NCI-MATCH looking at it from a certain perspective? Or what would you want to do as a next step, ideally if you had the funding and the pharma support? Dr. Jun Gong: That's the million dollar question. So just from the broad strokes, I think what these two back to back papers and studies comment is that amplifications may not be the more targetable of FGFR subset, but there is avenue for improvement there and further investigation. FGFR fusions and mutations however seem to go along with what we know in some of the FDA approved types now. Now the next step is in the area of precision oncology is could we expand the label indications now to other subtypes with FGFR fusions and mutations. And this is I think following precedent. You and the audience may know that there are a lot of different tumor agnostic approvals now for both immunotherapy and other targeted therapy types. So I think the goal of this study was to provide momentum for, perhaps, advancements into a tumor agnostic indication for FGFR inhibitors.  And we do cite in the K2 manuscript the results of a phase II study that was also published around the time we were writing the study up. It was the phase II RAGNAR study. And that enrolled patients, again, with FGFR fusions and mutations. And that trial was positive, too. That one was a larger study of 217 subjects. We highlight some differences in study populations as to why maybe the difference in responders were detected. Both were positive studies. It was reassuring that the overall survival impulse studies were about the same. And again, I think they don't compete. I rather think they complement each other in providing this body of evidence that  may meet- at one point, the FDA should be approached with this evidence for a tumor agnostic mutation so that more patients with this subset could be benefitting.  Dr. Rafeh Naqash: Excellent. Thank you so much, Jun.  Now, could you tell us briefly what your background is, where you've trained, and your interests, and how you balance clinical research with some of your personal interests?  Dr. Jun Gong: Sure. Thank you for that interest. I did my training in medical school in New York. I went to New York Medical College. And then I did my residency at Cedars-Sinai for medicine. And I went to City of Hope for fellowship where I was trained in GU by Dr. Monty Powell who maybe you folks are familiar with. And my GI training was with Dr. Fakih at City of Hope. And since then I returned back to Cedars-Sinai where I serve as a dual GI/GU focused medical oncologist. I do clinical trials in both and translational science, really focused on targeting tumor metabolism in both as well. My advice to the listeners and trainees and I tell my own fellows this, I think it's very rare now unless you're in phase I to do a dual focus. So I actually emphasized to my trainees that the more focused you can be, the better. Unless you are going into phase I, for example. With that, you can hone in, develop your craft. But then again, I have known several mentors who do multiple tumor types. But I think the more traditional mechanism is to focus as much as you can is my advice for the listeners.  Dr. Rafeh Naqash: Thank you again, Jun, for all those interesting scientific and personal insights. We appreciate you and working with JCO Precision Oncology for both of your manuscripts. This is the first time we have ever invited a lead author for two manuscripts at the same time. It's always good to be the first in something, and I learned a lot and hopefully, our audience would have learned a lot. Dr. Jun Gong: Thank you, Dr. Naqash, for having me. It was a pleasure speaking with you and the crew. Dr. Rafeh Naqash: Thank you.   Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experiences, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Click here to send us a text message!Many thanks to Robert J. Wolf, MD, for joining me on this episode of "The Art of Medicine with Dr. Andrew Wilner." Dr. Wolf is a practicing neuroradiologist and author of “Not a Real Enemy,” an historical narrative based on his father's remarkable experiences as a Hungarian Jew before, during, and after the Nazi Occupation. Wolf's Grandfather and Grandmother, like almost another half-million Hungarian Jews, were imprisoned by the Nazi's and died at the infamous prison camp Auschwitz. His father narrowly escaped and eventually had a successful OB-GYN practice in the USA, delivering 10,000 children! During our 30-minute discussion, Dr. Wolf tells us about his parents, the detailed notes they left of their lives, and how he came to write this compelling, historically accurate, biography of his father's harrowing and courageous exploits. To learn more or to contact Dr. Wolf: http://www.robertjwolfmd.com For another fascinating interview that touches on the sensitive topic of anti-semitism, please check out this episode with Edward Halperin, MD, a pediatric radiation oncologist, and Chancellor and Chief Executive Officer of New York Medical College, Valhalla, NY, who tells an unbelievable story of anti-semitism in Montreal:https://www.youtube.com/watch?v=istDy48DNOE Thanks for listening!Please click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com To support this program: https://www.patreon.com/andrewwilner Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: ...

Welcome to Imperfect Progress!! We're talking all things KNEE PAIN today with Orthopedic Surgeon Dr. Howard Luks who specializes in sports medicine. Dr. Luks was Chief of Sports Medicine and Arthroscopy at New York Medical College for over 20 years, where he taught the next generation of Orthopedic Surgeons about the needs of athletes of all ages.  Inside the podcast I ask the burning questions about: When you push through knee pain, and when is it a sign to dial it back? The complexities of inflammation and pain management. When knee surgery might be necessary and who is a suitable candidate. Mysteries of joint health and aging. Are your joints really "torn" or wearing out? Why can some people run marathons well into their 80s, while others struggle with joint agony in their 40s? Dr. Luks shares insights into the impact of factors like excess weight, diet, and lifestyle on inflammation and joint pain, offering a holistic perspective on the issue. We explore intriguing new research emerging from GLP-1 drugs like Ozempic, which show promise for alleviating joint pain (this is INTERESTING!). Dr. Luks provides valuable advice on steps patients can take before considering knee surgery, emphasizing the importance of holistic approaches to joint health. And finally, we confront the realities of aging and joint pain, discussing how individuals can navigate these challenges while maintaining an active lifestyle. If you're anything like me, you NEED this episode! Tune in today and embark on this enlightening journey with Dr. Howard Luks, uncovering the secrets to managing knee pain and optimizing joint health.

In this episode, I talk with orthopedic surgeon and sports medicine specialist, Dr. Jervis Yau, MD. We discuss a wide range of topics including hip impingement, rotator cuff tears, PRP and stell cell injections and ACL recontructions. Dr. Yau has a particular interest in minimally invasive techniques of the shoulder, knee, hip, elbow and ankle, as well as joint preservation and cartilage restoration procedures. He has published articles in peer-reviewed publications, books and orthopedic presentations dedicated to sports medicine and orthopedic conditions and treatments. Dr. Yau graduated from the University of California, San Diego and completed his Doctor of Medicine at New York Medical College where he was elected to the Alpha Omega Alpha Honor Medical Society. He completed his orthopedic surgery residency at Yale New Haven Hospital, Yale University School of Medicine, followed by his sports medicine fellowship at Sports Orthopedic and Rehabilitation (SOAR). If you enjoyed this episode, please consider leaving a 5-star review for my podcast. It really helps the podcast build momentum and reach more people.  Click HERE to learn more about Dr. Yau's clincial practice in Santa Barbara, CA. Click HERE to learn more about my book. 

Today we are privileged to have Doctor Kevin Chu with us. He is a private practice urologist and men's health specialist in Los Angeles, California. With roots in Pittsburgh, Pennsylvania, he pursued his undergraduate studies at UC Berkeley before attending medical school at the esteemed New York Medical College. Dr. Chu honed his expertise in urology through rigorous training at the University of Miami.   Shockwave therapy, originally developed for kidney stones, utilizes acoustic waves to induce a response in targeted tissues. While the mechanism for kidney stones involves breaking them up, shockwave therapy for ED operates differently. It stimulates the body's natural healing response, promoting neovascularization and tissue regeneration in the penis.   Addressing common concerns, Dr. Chu clarifies that shockwave therapy sessions are non-invasive and generally well-tolerated, with minimal side effects such as mild tingling or bruising. However, he emphasizes the importance of patient selection, cautioning that not all individuals may benefit equally from this treatment.   For more free erectile dysfunction education and resources, please visit: https://erectioniq.com/    Mark Goldberg helps men resolve erectile dysfunction. He offers individual, one-on-one services to men throughout the world through a secure, telehealth platform. It's 100% confidential. You can visit the Center for Intimacy, Connection and Change website to schedule a free consultation: https://centericc.com/

Alis Dicpinigaitis (1) and Dr. Fawaz Al-Mufti (2) join JNIS Editor-in-Chief, Dr. Felipe C. Albuquerque, to discuss the study, "Mapping geographic disparities in treatment and clinical outcomes of high-grade aneurysmal subarachnoid hemorrhage in the United States". They explain the findings of their study, covering the predictive impact of factors including age, insurance status, race, and hospital ownership. Read the paper: https://jnis.bmj.com/content/early/2024/02/19/jnis-2023-021330  (1) New York Presbyterian - Weill Cornell Medical Center, New York, New York, USA (2) Department of Neurosurgery, Westchester Medical Center at New York Medical College, Valhalla, New York, USA Please subscribe to the JNIS Podcast via all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify, to get the latest episodes. Also, please consider leaving us a review or a comment on the JNIS Podcast iTunes page: https://podcasts.apple.com/gb/podcast/jnis-podcast/id942473767  Thank you for listening! This episode was produced and edited by Brian O'Toole. 

Thomas Mustac is Otter PRr's medical and health industry PR specialist. His work helps brands in these complex industries navigate issues including — and especially — crisis communication. We discussed all of this and more this week on the On Brand podcast. About Thomas Mustac Thomas Mustac is Otter PRr's medical and health industry PR specialist. He previously held positions at the Dr. Oz Show and New York Medical College. He has his Master's Degree from Iona University and received an Advanced Certification in Nonprofit Public Relations. He has a diverse background in healthcare, pharmaceutical, telehealth, tech, cosmetics, sports, and interior design public relations. From the Show What brand has made Thomas smile recently? Working in crisis PR, Thomas pointed us to Zara's recent PR challenges. Connect with Thomas on the OtterPR website and on LinkedIn. As We Wrap … Listen and subscribe at  Apple Podcasts, Spotify, Amazon/Audible, Google Play, Stitcher, TuneIn, iHeart, YouTube, and RSS. Rate and review the show—If you like what you're hearing, be sure to head over to Apple Podcasts and click the 5-star button to rate the show. And, if you have a few extra seconds, write a couple of sentences and submit a review to help others find the show. Did you hear something you liked on this episode or another? Do you have a question you'd like our guests to answer? Let me know on Twitter using the hashtag #OnBrandPodcast and you may just hear your thoughts here on the show. On Brand is a part of the Marketing Podcast Network. Until next week, I'll see you on the Internet! Learn more about your ad choices. Visit megaphone.fm/adchoices

In today's episode we are discussing hair growth and hair restoration tips! We have the esteemed Dr. Alan J. Bauman a Hair Transplant Surgery Specialist in Boca Raton, FL and has over 28 years of experience in the medical field. In this episode Dr. Bauman shares the main causes of hair loss in both men and women, the best treatment options available today and how hair transplants has changed through the years.Learn more about Dr. Alan J. Bauman:Dr. Alan Bauman, MD is a Hair Transplant Surgery Specialist in Boca Raton, FL and has over 28 years of experience in the medical field. He received his Medical Doctor degree from New York Medical College in Valhalla, NY and had internship and residency training in surgery at Beth Israel Medical Center and Mt. Sinai Medical Center in Manhattan before specializing in hair transplant surgery and the treatment of hair loss, including primarily androgenetic alopecia or hereditary male or female pattern hair loss.Dr. Bauman came to national prominence in 2006 for his role in pioneering eyelash implants at the world's first International Society of Hair Restoration Surgery (ISHRS) Live Surgery Workshop for Eyelash Transplantation[11] in Torrance, California.Learn more about today's guest at https://www.baumanmedical.com/ and be sure to check out his hair stimulation cap at https://shop.baumanmedical.com/products/lasercap-as-seen-on-tv-dr-bauman-on-the-doctorsWays to work with Rachel Varga!FREE 30-minute Biohacking For Ageless Beauty Training! https://www.theschoolofradiance.com/freebiesDownload Radiance: The New Skin Science on Audible!Book a One-on-one with Rachel Varga for customized skin care, rejuvenation guidance, and ongoing support! https://www.theschoolofradiance.com/consultation and use code Podcast15!Shop skincare, make-up, hair/skin/nail supplements, grooming tools, dermal rollers, and much more! https://alwaysradiantskinshop.com/Register for my next weekly LIVE and FREE Masterclass on various topics where I answer your questions! https://us02web.zoom.us/meeting/register/tZwuceioqTwiE9O1K1fF1vnLqZBlCvPdkDWc The video replays (which are highly interactive) are available on my skin shop for a small fee here!Join Seasonal Skincare Expert Tutorials on skincare, makeup, hair care (and growth), biohacking, clean peels, pre and post-rejuvenation tips, dermal rolling, and advanced at-home technologies for the face and body! https://www.theschoolofradiance.com/Join The School of Radiance Membership for your personal radiant transformation by cultivating resilient radiance through detoxing from environmental toxins, enhancing communication, enhancing relationships, etiquette, and much more: https://www.theschoolofradiance.com/membershipAs a disclaimer, please note that the information shared in this podcast and interview is not to be taken as medical advice, and it's always important to consult with your physician before making any lifestyle changes. Rachel disclaims any responsibility for inaccurate credentials of guests or information used that may cause harm.Thank you for tuning in to this episode of The School of Radiance with Rachel Varga (formerly The Rachel Varga Podcast and The Always Radiant Skin Podcast)!Rachel Vargainfo@theschoolofradiance.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

#295 Guy welcomed Lawrence Edwards back in the show. He discussed the journey of spiritual awakening and the soul's evolution in this podcast episode.He emphasized the importance of adding fullness to life rather than getting rid of the finite aspects. Lawrence shared insights on the hero's journey, shedding limitations, and the pursuit of knowing the divine within. He highlighted the significance of surrender, intense practice, and the presence of divine support in spiritual growth. Lawrence also touched on the concept of dharma, living in alignment with the highest wisdom, and the motivation to uplift all beings. The episode concluded with Lawrence encouraging listeners to walk the path of higher wisdom and empowerment in everyday life. About Lawrence: Lawrence Edwards is a neurotherapist, psychotherapist, and an expert in Kundalini Awakening, our innate power of Consciousness that creates the highest order of transformation and revelation. This power is the foundation of all yogic, mantra and meditation practices. Lawrence is regarded by many as a modern mystic known for his love of the Divine. He is unusual in this field because he has a deep grounding in both Eastern and Western traditions, and applies them both to his work with Kundalini. His personal, direct, life-long experience of the extraordinary power and grace of Kundalini are reflected in his writings, teaching and poetry.  His experiences began early in life and he says Kundalini's grace continues to be the essence of his life. Lawrence is the president of The Kundalini Research Network, as well as the founder of a Kundalini support website, KundaliniSupport.org. He is the founder and director of the Anam Cara Foundation and a contributing author to the Sounds True anthology Kundalini Rising: Exploring the Energy of Awakening. Lawrence has practiced and taught meditation for over 46 years and has been on the faculty of New York Medical College since 1998. He is the author of the critically acclaimed book on Kundalini, The Soul's Journey: Guidance From The Divine Within and Kali's Bazaar. He leads retreats on the Mysteries of the Divine Feminine and Awakening Kundalini. Key Points Discussed:  (00:00) - Most PROFOUND Explanation On Human Suffering. (04:54) - Long love affair with goddess. (09:27) - The hero's journey. (15:06) - The mind in absolute silence. (20:25) - Embracing oneness for collective awakening. (27:20) - Living dharmically in the world. (29:17) - Mystics' opposition to religions. (36:09) - Evolution of consciousness. (42:35) - Support from beings on other levels. (44:19) - The paradox of spiritual practice. (49:05) - Rapture and ecstasy in meditation. How to Contact Lawrence Edwards: Twitter - twitter.com/MeditationDoc Website - www.thesoulsjourney.com   About me:My Instagram: www.instagram.com/guyhlawrence/?hl=en Guy's websites:www.guylawrence.com.au www.liveinflow.co''

All of us have some element of addiction. It could be to achievement, it could be to sugar, it could be to alcohol, it could be to medications, it could be anything. Join my special guest today, Dr. Courtney Barrows McKeown, as she shares her experience of pulling it all back together and thriving after struggling with addiction, to spinning out of control, to having her medical license suspended and even being hospitalized after a psychotic episode. “I was trying to cover it all up. I certainly was too terrified to admit to anybody. And so they just thought I was having a ‘mental breakdown' or whatever.” -Dr. Courtney Barrows McKeown About Dr. Courtney Barrows McKeown Courtney Barrows McKeown, MD is a board-certified general surgeon. She earned her medical degree at New York Medical College, graduating Alpha Omega Alpha. She completed her general surgery residency training in 2020 at Beth Israel Deaconess Medical Center in Boston, MA, and received additional subspecialty training in hepatopancreatobiliary (HPB surgery) in the Midwest. She started her career as a community general surgeon in New Hampshire, and is excited for her next opportunity, where she will be moving to TN to join Dr. Vertrees' Columbia Surgical Partners as a general surgeon.Dr. Barrows McKeown recently sat down for an interview and wrote a follow up article on Rethinking Residency, where she shared her story of struggling with perfectionism, mental health, and addiction during training - including the trials and tribulations she faced and the barriers she overcame to get her health and career back on track. She has recently partnered with the Dr. Lorna Breen Heroes' Foundation to advocate, increase awareness, and identify solutions to promote physician health and well-being. She is grateful to be celebrating three years of recovery next month. Her mission is to provide hope and mentorship to other early career physicians who may be struggling with similar issues she faced, reduce stigma, and help drive systemic changes in order to make our professional climate better for the next generation of surgeons.In her free time, Dr. Barrows McKeown enjoys spending time with her husband and their dog Buddy, golfing, kayaking, and is an avid Boston sports fan. Find Out More https://rethinkingresidency.com/wellness/overcome-early-career-physician-setbacks/ https://rethinkingresidency.com/wellness/overcoming-addiction-in-residency/ Facebook - https://www.facebook.com/courtney.barrows Linked In - www.linkedin.com/in/courtney-barrows-mckeown-md Instagram - @courtb_mckeown_md

Today we are joined by Dr. Howard Luks. Howard is a Board Certified Orthopedic Surgeon specializing in sports medicine and has been the Chief of Sports Medicine and Arthroscopy at New York Medical College for over 20 years.Howard teaches us why it's important to not fear exercise, but rather to fear being sedentary. We dive into...How pain is a symptom of poor metabolic healthExercise is our best bet to combat poor metabolic healthThe truth about imagingOsteoarthritis and how to educate a client who is worried about harming the joints if they exercise or runAerobic conditioning misconceptionsBe sure to follow Howard on Instagram @hjluks1Check out his book: Longevity…SimplifiedI apologize for the audio at the end of the episode. If you'd like the transcript, send me an email mallory@reloadpt.com and I'd be happy to send it to you.How to work with us:Learn about fitness services at Reload hereLearn about physical therapy services at Reload hereIG: @reload.ptDiggin' the intro/outro jam? Check out my friend, Joe Spinelli on SoundCloud! 

Nutrition has vast effects on individual and population health—impacting obesity rates, chronic conditions, and quality of life. Yet despite its proven, wide-reaching effects, nutrition remains largely overlooked as a social determinant of health. Dr. Livia Santiago-Rosado, MD, Commissioner of the Dutchess County (NY) Department of Behavioral and Community Health, joins Dr. Enrique Enguidanos to discuss this important topic and how communities can work together to make small tweaks and big impacts. Bio:Dr. Santiago-Rosado has been Commissioner of the Dutchess County Department of Behavioral Health since her appointment in December 2021. Following completion of a BA in Biological Anthropology summa cum laude from Harvard University, she attended medical school at Columbia University. Having completed residency training at Mount Sinai and Elmhurst Hospitals in New York City, has practiced Emergency Medicine in New York for over two decades, working in emergency departments (EDs) in diverse settings including urban, suburban, rural, public and private. She holds an academic appointment as Distinguished Visiting Professor at New York Medical College and Adjunct Associate Professor at the Touro School of Osteopathic Medicine.Dr. Santiago has dedicated her career to working with and enhancing the care of underserved populations. Prior to moving to Dutchess County, she spent 15 years as a clinical leader in New York City's public hospital system, Health + Hospitals (H+H), where she helped found a novel ED Care Management program for highly vulnerable patients and the first ED-based observation unit in H+H. Prior to her current appointment, Dr. Santiago was the Medical Director and inaugural Chair of Emergency Medicine at Vassar Brothers Medical Center in Poughkeepsie, NY. Dr. Santiago is an active member of the New York State Association of County Health Officials (NYSACHO) and sits on its Emerging Issues committee. She also currently serves as a Councilor representing New York at the American College of Emergency Physicians (ACEP) and has served two terms on the Board of Directors for the New York Chapter of ACEP. She also serves on ACEP practice committees at both the State and national levels. Throughout her career, she has led and participated in policy development, education, informatics and data analytics, quality improvement, change management, and research in Emergency Medicine, social determinants, and population health at the local, state, and national levels. Lastly, since local health commissioners in New York are required to have a master's degree in public health (or related field) in addition to a medical doctorate, she is currently enrolled in the MPH program at the University at Albany.

Join us for an illuminating conversation with Dr. Eric Rosenberg, a distinguished Cornea and Complex Anterior Segment Surgeon at SightMD and Assistant Professor of Ophthalmology at New York Medical College. With a passion for education and a keen interest in the fusion of technology, engineering, and medicine, Dr. Rosenberg is at the forefront of innovation in ophthalmology. He serves on the executive Digital Committee at ASCRS and is a co-founder of MetaMed Media.Some of the episode highlights include: Journey into Eye Care industry: Dr. Rosenberg shares his unexpected path into ophthalmology, discussing the moments that ignited his passion for the field of eye care and more. Professional Odyssey: Explore his career trajectory, from residency, to fellowship at Weill Cornell, to being a professor and then diving into eyetech. Digital Visualization: Understand the importance of digital visualization in modern ophthalmology and eye care to help transform diagnostics, treatment planning, and patient education.MetaMed Media's Metaverse:   Learn about Dr. Rosenberg's groundbreaking initiative – a metaverse designed specifically for Eye Care Professionals (ECPs). Discover how this innovative platform addresses challenges and fosters collaboration within the eyecare and healthcare community.  Smart Solutions in Eye Care: Gain insights into his  vision for the future of eye care, where smart solutions powered by artificial intelligence, augmented reality, and telemedicine play pivotal roles in enhancing patient care, accessibility, and efficiency. & much more...  Along with all of the learnings check out our fun game segment "This or That " to get some interesting insights about our guest.Guest LinkedIn profile: Dr. Eric Rosenberg: https://www.linkedin.com/in/student4life/MetaMed Media: https://www.metamedmedia.com/ Thanks for listening! Follow us on LinkedIn, Instagram, Youtube and Facebook.Please leave me a review if you enjoyed my episodes: https://www.nerdyoptometrist.com/reviews/new/Support the show Support the showThanks for listening! Follow us on LinkedIn, Instagram, Youtube and Facebook. Please leave me a review if you enjoyed my episodes.

In this podcast, Dr. Tetyana Cheairs gives a detailed overview of the fertilized egg model and how it is currently being used in safety assessment studies. She then describes important ways in which toxicologists and drug development programs could benefit from utilizing the fertilized egg model. This podcast is incredibly informative and is tailored to be understood and enjoyed by a broad scientific audience. Dr. Cheairs is an Assistant Professor of Pathology, Microbiology, and Immunology at New York Medical College, where she leads an innovative research program focused on using nonanimal models to study the hazardous effects of chemicals. As a result of her active involvement in teaching activities, she was appointed as Assistant Dean for PhD Programs at the Graduate School of Biomedical Sciences in 2019.

In this episode of the BackTable Podcast, guest host Dr. Krishna Amuluru interviews Dr. Fawaz Al-Mufti about recent trials on large core strokes and how they may impact practice. Dr. Al-Mufti is a practicing neurointerventionalist and serves as the Associate Chair of Neurology for Research at New York Medical College. Dr. Al-Mufti examines the cost-effectiveness and socioeconomic implications of successful treatment of patients with large core strokes. The doctors highlight various stroke thrombectomy trials including the RESCUE-Japan, SELECT2 Trial, and TENSION trials. The discussion also covers how these findings affect thrombectomy expansion in lower resource settings and the future outlook of endovascular thrombectomy procedures. --- CHECK OUT OUR SPONSOR RADPAD® Radiation Protection https://www.radpad.com/ --- SHOW NOTES 00:00 - Introduction 02:53 - Large Ischemic Core Infarcts 06:06 - The Importance of ASPECTS 11:59 - Large Ischemic Core Trials 23:37 - Socioeconomic Implications of Thrombectomy 38:08 - The Future of Thrombectomy --- RESOURCES Mission Thrombectomy: https://missionthrombectomy.org/ The Alberta Stroke Program Early CT score (ASPECTS): A predictor of mortality in acute ischemic stroke: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515558/ Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomized trials (HERMES Study): https://doi.org/10.1016/S0140-6736(16)00163-X Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging (DEFUSE III Trial): https://www.nejm.org/doi/full/10.1056/nejmoa1713973 Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct (DAWN Trial): https://www.nejm.org/doi/full/10.1056/nejmoa1706442 Endovascular Therapy for Acute Stroke with a Large Ischemic Region (RESCUE-Japan Trial): https://www.nejm.org/doi/full/10.1056/nejmoa2118191 Trial of Endovascular Thrombectomy for Large Ischemic Strokes (SELECT2 Trial): https://www.nejm.org/doi/full/10.1056/NEJMoa2214403 TESLA Trial: Rationale, Protocol, and Design: https://www.ahajournals.org/doi/10.1161/SVIN.122.000787 Endovascular thrombectomy for acute ischaemic stroke with established large infarct: multicentre, open-label, randomized trial (TENSION Trial): https://www.sciencedirect.com/science/article/pii/S0140673623020329 Evaluation of acute mechanical revascularization in large stroke (ASPECTS ⩽5) and large vessel occlusion within 7 h of last-seen-well: The LASTE multicenter, randomized, clinical trial protocol: https://pubmed.ncbi.nlm.nih.gov/37462028/ Trial of Endovascular Therapy for Acute Ischemic Stroke with Large Infarct (ANGEL-ASPECT Trial): https://www.nejm.org/doi/full/10.1056/NEJMoa2213379 Acute endovascular stroke therapy (Dr. Mike Chen Review): https://pubmed.ncbi.nlm.nih.gov/20535000/ Mechanical thrombectomy is cost-effective versus medical management alone around Europe in patients with low ASPECTS (European Cost Effectiveness Study): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313965/ Mechanical Thrombectomy Global Access For Stroke (MT-GLASS): A Mission Thrombectomy (MT-2020 Plus) Study: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313965/ Noncontrast Computed Tomography vs Computed Tomography Perfusion or Magnetic Resonance Imaging Selection in Late Presentation of Stroke With Large-Vessel Occlusion: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576630/

According to the 1964 Mary Poppins children's film, "just a spoonful of sugar" is said to make the medicine go down. But what if we say that those daily spoons of sweetness may actually result in the need for kids to take medication? According to the American Diabetes Association, approximately 30 million people in the United States alone in 2021 were diagnosed with diabetes mellitus, Types I and II combined, with 352,000 of these being under the age of 20. Diabetes is a chronic condition influenced by the body's inability to either produce the insulin hormone or effectively utilize it. Truly, hormones and their balance influence the optimal functioning of the human body, especially in the youth. According to the American Board of Pediatrics, if left untreated, diabetes and other leading chronic diseases influenced by hormones, such as obesity, can lead to detrimental health concerns, such as cardiovascular disease and mortality. Endocrinology is the complex field of hormones and their equilibrium, and there is no space for sugarcoating in this domain.We are joined in this episode by Dr. Sheila Pérez-Colón, a board-certified pediatric endocrinologist based in Puerto Rico. She received her BS in Biology from the University of Puerto Rico, MD from the Universidad Autonoma de Guadalajara with its pathway completion at New York Medical College (where she attained a #1 class rank), Pediatrics Residency at Maimonides Medical Center/Infants and Children's Hospital of Brooklyn, and Pediatric Endocrinology fellowship at SUNY Downstate Health Sciences University where she later served as an Assistant Professor of Medicine. Dr. Sheila became an attending physician in offices across the United States, having been the Diabetes Clinic Director at Kings County Hospital in New York City, Baptist Health South Florida, and Kaiser Permanente in Los Angeles. Having moved back to Puerto Rico in 2020 to serve her homeland, she currently stands as the Owner of Elite Endocrine MD, a direct specialty care practice that focuses on pediatric diabetes, obesity management, thyroid disorders, and pubertal disorders. Dr. Sheila has over 15 publications on prediabetes, autoimmune thyroiditis, and adolescent obesity and has been featured on Yahoo! News and Everyday Health.Livestream Air Date: March 28, 2023Follow Sheila Pérez-Colón, MD: Instagram, FacebookFollow Friends of Franz Podcast: Website, Instagram, FacebookFollow Christian Franz Bulacan (Host): Instagram, YouTubeThankful to the season's brand partners: Covry, House of M Beauty, Nguyen Coffee Supply, V Coterie, Skin By Anthos, Halmi, By Dr Mom, LOUPN, Baisun Candle Co., RĒJINS, Twrl Milk Tea, 1587 Sneakers

Support Lorenzo on Patreon.com Guest speaker: John Beresford PROGRAM NOTES: Dr. John Bereford delivering this talk in 2006 at the conference celebrating Albert Hofmann's 100th birthday. Today's program features a lecture by psychedelic researcher Dr. John Beresford. Here is Erowid's introduction to him: "British-born John Beresford began his psychedelic research interests in 1961, and shortly thereafter he resigned his post as an Assistant Professor of Pediatrics at New York Medical College. In 1963 he founded the Agora Scientific Trust, the world's first research organization devoted to investigating the effects of LSD. In contrast to Leary's invitation to "tune in, turn on, and drop out", Beresford initially wanted to keep LSD as a tool of scientifically trained specialists. However, later in his life he adopted a viewpoint that was opposed to the medicalization of psychedelics." Of course, the story that he is best known for is the time that he wrote to Sandoz Laboratories and requested one gram of LSD! (If my math is correct, that's about 4,000 doses of 250 mics each.) Amazingly, Sandoz sent him a gram through the mail and attached a note that read, "Good luck." The talk we are about to listen to was given by Dr. Beresford at the conference celebrating Albert Hofmann's 100th birthday. He titled it: "Psychedelic Agents and the Structure of Consciousness: Stages in a Session Using LSD and DMT".

EPISODE #964 BODILY AUTONOMY AND INFORMED CONSENT Richard speaks with a medical doctor and pain management specialist about issues surrounding medical freedom, such as bodily autonomy, informed consent and the freedom to be free from coercion when it comes to medical interventions. GUEST: Dr. Irene Mavrakakis, M.D is the Founder of Liberty Speaks and Delaware Initiative for Science and Ethics. She is a Christian and a Mises Caucus Libertarian who is a staunch medical freedom, bodily autonomy, and informed consent advocate. Promoting and implementing Free and Equal Elections, Polling, and Debates are advocacy projects she prioritizes in addition to her libertarian and peace projects. She is Vice Chairwoman of the Libertarian Party of Delaware, Kent County Chairwoman of the Libertarian Party of Delaware, a Rage Against the War Machine Organizer, a Humanity for Peace Organizer, Captain/Health Officer Dover Composite Squadron Delaware Wing Civil Air Patrol U.S Air Force Auxiliary, a Student Pilot, and a Project Manager/Advisor to the Mike ter Maat for President Campaign. Professionally, she is an interventional spine and musculoskeletal specialist. Additionally, she advocates for health and wellness via nutrition and detoxification that leads to a homeostatic biochemical and microbiological terrain. She is board certified in Anesthesiology and subspecialty board certified in Pain Medicine.  She obtained a Bachelor's degree in biology from New York University and her Doctor of Medicine Degree from New York Medical College.  She is honored and grateful to be a new addition to the Free and Equal Team. She has two adult children, Bobby and Julia who she is incredibly proud of and are the lights of her life. She dedicates her advocacy work to her mom, Christina who was a Lebensborn child during WWII and came to America because she knew she would “ always be free” and whose family hid Jewish families during the Holocaust and her dad, Christos, may his memory be eternal, whose family also hid Jewish families. WEBSITE: https://libertyspeaksinc.com SUPPORT MY SPONSORS!!! DraftKings Sportsbook–an Official Sports Betting Partner of the NFL Download NOW and use code STRANGEPLANET to sign up! New customers can take home TWO HUNDRED DOLLARS IN BONUS BETS INSTANTLY just for betting five bucks. FACTOR MEALS - HEALTHY EATING, MADE EASY!!! Factor, America's #1 Ready-To-Eat Meal Kit, can help you fuel up fast with chef-prepared, dietitian-approved ready-to-eat meals delivered straight to your door. Head to https://www.factormeals.com/rssp50 and use code rssp50 to get 50% off! COPY MY CRYPTO https://copymycrypto.com/richard Discover how over 2,800 people - many of who know nothing about crypto or how to invest - are building rapid wealth the cabal can never steal. "You don't need to know a thing about cryptocurrency if you copy someone who does." Gain Access for just $1 https://copymycrypto.com/richard BECOME A PREMIUM SUBSCRIBER!!! https://strangeplanet.supportingcast.fm Use the discount code "Planet" to receive one month off the first subscription. We and our partners use cookies to personalize your experience, to show you ads based on your interests, and for measurement and analytics purposes. By using our website and services, you agree to our use of cookies as described in our Cookie Policy. Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://strangeplanet.supportingcast.fm/

Dr. Catherine G. Caronia is a highly accomplished and dedicated professional in the field of pediatrics and medical education. Based in Syosset, New York, she has a wealth of experience and expertise in various roles, including Senior Vice President of Academic Affairs and Chief Academic Officer at Catholic Health, Editor of the Academic Journal of Pediatrics and Neonatology, and Designated Institutional Officer at Good Samaritan Hospital.Dr. Caronia is a board-certified pediatrician with a subspecialty in Pediatric Critical Care. Her commitment to medical education is evident through her role as Associate Dean of the Clinical Affiliate Site of the Icahn School of Medicine at Mount Sinai and her positions as Clinical Professor and Associate Dean at various medical institutions.With a diverse educational background, including an M.D. from New York Medical College and an M.B.A. from Adelphi University, Dr. Caronia brings a unique blend of medical and business acumen to her leadership roles in healthcare. Her passion for research and continuous improvement is reflected in the numerous grants and studies she has undertaken, particularly in the field of pediatrics.Dr. Caronia is a Fellow of the College of Chest Physicians and the American Academy of Pediatrics, and she has received various awards for her contributions to healthcare, including the Catholic Health Good Samaritan University Hospital Physician of the Year.Beyond her professional roles, Dr. Caronia actively engages in committee work and community involvement, emphasizing her dedication to enhancing the quality of healthcare and education. Her work is widely recognized and respected within the medical community, making her a valuable asset to healthcare organizations and institutions.Support the show

According to the APA Dictionary of Psychology, burnout is defined as “physical, emotional or mental exhaustion, accompanied by decreased motivation, lowered performance and negative attitudes towards oneself and others.” This is what our storytellers are experiencing in this week's episode. Part 1: During her pediatric residency, Erica Martinez finds herself struggling to feel empathy for some of her patients. Part 2: While working as a doctor in South Bronx, Karinn Glover feels overwhelmed and powerless when trying to help a patient with substance use issues. Erica Martinez is a physician finishing her last year of a three year residency training in pediatric medicine. Originally from Minnesota, she moved east for college and earned her MD from New York Medical College. She is passionate about both children's health and physician wellness, and she enjoys knitting tiny baby hats in her spare time. After graduating from Howard University with a BA in History, Dr. Glover worked at Essence Magazine and as an Account Executive for Verizon. She followed her curiosity about medicine and ultimately attended SUNY Downstate College of Medicine and obtained an MPH from Columbia University's Mailman School of Public Health. Currently Assistant Professor of Psychiatry at the Albert Einstein College of Medicine, Dr. Glover teaches psychopharmacology and psychotherapy to Psychiatry and Family Medicine residents. Her career as a consultant and educator have informed her expertise in the fields of health equity, workplace mental health, and organizational success. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Paul D Corona MD was born and raised in Southern California. He attended the University of Southern California from 1980-1984, receiving a BS degree in Biology/Premed. From there he went to Medical school at New York Medical College, and then a three - year residency program in family practice at California Hospital in Los Angeles. After the first decade in Family Medicine, he decided to move full time into psychiatry, combining both into "Mind Body Medicine." He then decided to dedicate the rest of his career to patient care and teaching patients and Doctors alike the emotional and physical benefits of “this revolutionary medical solution. “ http://www.drpaulcoronamd.com Sign up for 10% off of Shrink Rap Radio CE credits at the Zur Institute

How do parents cope with an ADHD kid? Dr. Mark Bertin, developmental pediatrician has said that “ADHD tends to push parents away from the exact parenting approaches that best address ADHD.” In this conversation we talk about how parents can best help ADHD kids…and themselves!  If you enjoyed this episode, and it inspired you in some way, I'd love to hear about it and know your biggest takeaway. Take a screenshot of you listening on your device, post it to your Instagram stories, and tag me @mindfulmamamentor. Have you left a review yet? All you have to do is go to Apple Podcasts or  Stitcher (or wherever you listen), and thanks for your support of the show! Dr. Bertin is a developmental pediatrician and author of How Children Thrive, Mindful Parenting for ADHD, Mindfulness, and Self-Compassion for Teen ADHD, and The Family ADHD Solution, which integrates mindfulness into the rest of pediatric care. He is a contributing author of the book Teaching Mindfulness Skills to Kids and Teens. Dr. Bertin is on the faculty at New York Medical College and the Windward Teacher Training Institute, and on the advisory boards for the American Professional Society of ADHD and Related Disorders, Common Sense Media, and Reach Out and Read. His blog is available through Mindful.org, Psychology Today, and elsewhere. For more information, please visit his website at www.developmentaldoctor.com.  Get Hunter's best selling book, Raising Good Humans now! Over 200,000 copies sold! Click here to order and get book bonuses! And now Hunter's newly released book, Raising Good Humans Every Day, is available to order! Click here to get your copy! ABOUT HUNTER CLARKE-FIELDS: Hunter Clarke-Fields is a mindful mama mentor. She coaches smart, thoughtful parents on how to create calm and cooperation in their daily lives. Hunter has over 20 years of experience in mindfulness practices. She has taught thousands worldwide. Be a part of the tribe—we're over 25 thousand strong! Join the Mindful Parenting membership. Take your learning further! Get my Top 2 Best Tools to Stop Yelling AND the Mindful Parenting Roadmap for FREE at: mindfulmamamentor.com/stopyelling/ Find more podcasts, blog posts, free resources, and how to work with Hunter at MindfulMamaMentor.com. We love the sponsors that make this show possible! You can always find all the special deals and codes for all our current sponsors on our website: https://mindfulmamamentor.com/mindful-mama-podcast-sponsors/ Learn more about your ad choices. Visit megaphone.fm/adchoices

What is the most common sexual health issue that men/penis owners are experiencing or concerned with? What can go wrong if penis owners don't acknowledge their (sexual) health problems and seek help? Why is searching for “my dick can't get hard” or “lump in my balls” on the internet a problem? How can penis owners safely get good, accurate information online? How can they overcome cock-related health shame or embarrassment when it comes to addressing their sexual health concerns? And what advice do you have for partners or loved ones who want to support men in dealing with sexual health stigmas? About our guests: Dr. Kevin Chu grew up in Pittsburgh, Pennsylvania and attended the University of California - Berkeley for undergraduate school. He completed medical school at New York Medical College and his urology residency training and fellowship in Male Infertility and Sexual Medicine at the University of Miami. Currently, Dr. Chu is a private practice, men's health specialist in Los Angeles. He has published multiple papers on both male infertility and sexual health and is the current co-host of the men's health podcast Man Up: A Doctor's Guide to Men's Health. Dr. Justin Dubin grew up in Wayne NJ and attended Johns Hopkins University for undergraduate school. He completed medical school at Rutgers Robert Wood Johnson and his urology residency training at the University of Miami. Currently, Dr. Dubin is completing his fellowship in Male Infertility and Sexual Medicine at Northwestern University and will be starting up as the Director of Men's Health at Memorial Health Systems in Hollywood Florida. Dr. Dubin is passionate about men's health and education with the goal of improving both the lives of men and their partners. He has published multiple papers on both male infertility and sexual health, has been quoted in the NY Times, USA TODAY, Insider, and Men's Health and is the current co-host of the men's health podcast Man Up: A Doctor's Guide to Men's Health. To learn more go to themanuppod.com Join us November 1st-6th, 2023 for The Shameless Sex Retreat: Unleash Your Shameless Self - in Costa Rica! Spaces are limited to reserve your spot ASAP here Other links: Start meditating now with 40% off a Calm Premium subscription at www.calm.com/shameless Turbo charge your sex life and beyond AND get 15% off and other freebies with code SHAMELESS by going to Viiahemp.com Get 10% off + free shipping with code SHAMELESS on Uberlube AKA our favorite lubricant at uberlube.com Get 10% off while mastering the art of pleasure at  OMGyes.com/shameless Get 15% off all of your sex toys with code SHAMELESSSEX at purepleasureshop.com